| Entries |
| Document | Title | Date |
|---|
| 20080200545 | PEELING PROCESS WITH SURFACTANTS - Process for the treatment of, e.g., visible and/or tactile irregularities of human skin, by applying topically, to the skin, a composition containing, in a physiologically acceptable medium, at least 5% by weight of one or more surfactants comprising at least one alkyl chain having from 6 to 16 carbon atoms. | 08-21-2008 |
| 20080207754 | Method and apparatus for palatable prevention of acid reflux - A method and applicators for preventing or reducing acid reflux (or “GERD”) by delivering a proper dose of vinegar directly to the back of the throat without exposing the taste buds, and immediately followed by a shot of water or other pleasant tasting chaser to wash it down. One applicator generally comprises a joined pair of sealed flexible pouches each sealed by a seal that may be burst open on the application of pressure to the pouches in order to dispense the product therein. The first pouch is filled with a dose of undiluted apple cider vinegar (approximately 5 to 10 cc) and the second pouch is filled with a liquid chaser, usually distilled water. Another applicator generally comprises a drinking vessel defined by two side-by-side receptacles, and pair of fixedly attached straws each entering a corresponding receptacle. The straw entering the chaser is oriented at a fixed angle greater than the straw entering the vinegar so that vinegar pours first followed by the chaser. In use, the vessel is lifted to the mouth with both straws disposed at the back of the throat, and the vessel is tilted so that the vinegar receptacle pours first, followed immediately by the chaser. This results in the vinegar pouring directly down the throat without exposing the taste buds, and being immediately followed by the chaser to wash it down. | 08-28-2008 |
| 20080221211 | METHOD OF TREATMENT OF NEUROLOGICAL INJURY OR CANCER BY ADMINISTRATION OF DICHLOROACETATE - A method for treating neurological injury or cancer in a patient includes administration of a therapeutically-effective amount of dichloroacetic acid (DCA), a therapeutically-effective amount of electromagnetic radiation, or both to the patient. | 09-11-2008 |
| 20080234374 | Compositions and method for removing hair - The invention encompasses a composition for hair removal comprising at least one organic hair follicle penetrating agent and at least one enzyme inhibitor for the purpose of achieving permanent hair follicle inactivation, and methods for hair removal using the same. | 09-25-2008 |
| 20080249173 | Treatment of Apoptosis - A method is provided for treating a patient suffering from apoptosis of tissue comprising administering to that subject a therapeutically effective amount of one or more ketogenic compounds such that a physiological ketosis is produced sufficient to arrest said apoptosis. Preferably the apoptosis is of cerebral tissue such as that associated with acute intractible seizures, particularly with status epilepticus. The method is also applicable to apoptosis associated with administration of topic stuimuli for treatment of cancer, that produced by viral infections, autoimmune diseases or Aquired Immuno Defficiency Syndrome. The ketosis produced is a state in which levels of one or both of acetoacetate and (R)-3-hydroxybutyrate concentrations in the mood of the subject such that their total concentration in the blood is elevated above the normal fed levels to between 0.1 and 30 mM. Also provided is the use of ketogeic material to in the manufacture of a medicament for the treatment of apoptosis and pharmaceutical compositions for such treatment. | 10-09-2008 |
| 20080269328 | Effects of low n-6:n-3 fatty acid ratio from two dietary sources on plasma and tissue lipid composition - Health benefits from low n-6:n-3 fatty acid (FA) ratio on cardiovascular risk have been shown. However, the impact of the source of n-3 FAs has not been fully investigated. Our purpose was to investigate cardiovascular benefits of oils with a low ratio of n-6:n-3 FAs, but different sources of n-3 FAs. Mice were divided into 3 groups (n=7) and fed a diet supplemented with either a fish or flaxseed oil-based ‘designer oils’ with an approximate n-6:n-3 FA ratio of 2/1 or with a safflower-oil-based diet with a ratio of 25/1, for 16 weeks. Plasma lipids and fatty acid profile of the liver and heart tissues were characterized. Plasma cholesterol levels were reduced in both fish and flax groups by 27% and 36%, respectively, as compared to controls at endpoint. The levels of EPA and DHA in liver phospholipids were significantly increased in both fish and flax groups as compared to the control group, with more profound increases in the fish group. Arachidonic acid levels were similarly decreased in the liver tissues from both fish and flax groups as compared to controls. Our data indicates that health benefits may be achieved by lowering dietary n-6:n-3 FA even in a high fat diet medium. | 10-30-2008 |
| 20090012163 | Compositions containing Mg/Zn/F-CaP plus inhibitors of pro-inflammatory cytokines (alpha ketoalkanoic acid compound) for osteoporosis prevention, therapy and treatment of bone diseases - A method is described for the treatment of bone disease by oral dosing of a patient with an inhibitor(s) or pro-inflammatory Cytokines which are comprised of a combination of alpha ketoalkanoic acid admixed in a pharmaceutically acceptable carrier with calcium/phosphate/magnesium/zinc or strontium salt compound ion—a hydroxyapatite matrix. | 01-08-2009 |
| 20090023809 | HYDROGEN CYANAMIDE PESTICIDE FORMULATIONS - Agricultural crops are protected from the growth of undesirable vegetation as well as nematode and insect infestations, by the application of hydrogen cyanamide in combination with a short-chain, water-soluble monocarboxylic acid, with improved pesticidal effect. | 01-22-2009 |
| 20090042984 | Cool-Pet System - Included is an invention that deals with animal and pet nuisance, behavior control, obedience training, urinary and potty training, and repellent/discouragement method where a solution having vinegar and flavors being dispensed from a spray bottle is found to be effective in stopping or discouraging dogs, birds or animals from being noisy, being hyperactive, and behaving badly. The solution is also useful for obedience training purposes and can also be applied as a repellent/discouragement method when sprayed onto desired spots or onto the animal. | 02-12-2009 |
| 20090054522 | Hair Care Product - With an object of discovering a substance having a testosterone 5α-reductase inhibiting action, a hair papilla cell growth promoting action, a fibroblast growth factor-7 production promoting action, a vascular endothelial growth factor production promoting action or a bone morphogenetic protein-2 production promoting action, and of providing a hair care product having this substance blended therein, and a hair growth tonic, a testosterone 5α-reductase inhibitor, a hair papilla cell growth promoter, a fibroblast growth factor-7 production promoter, a vascular endothelial growth factor production promoter and a bone morphogenetic protein-2 production promoter each having this substance as an active ingredient thereof, a hair care product of the present invention is made to contain corosolic acid therein, and each of a hair growth tonic, a testosterone 5α-reductase inhibitor, a hair papilla cell growth promoter, a fibroblast growth factor-7 production promoter, a vascular endothelial growth factor production promoter and a bone morphogenetic protein-2 production promoter of the present invention is made to contain corosolic acid as an active ingredient thereof. | 02-26-2009 |
| 20090062389 | In-Shower Lotion Compositions Comprising Up to 10% Free Fatty Acids Wherein Ratio of Unsaturated to Saturated Fatty Acids is at Least 1:1 - This invention relates to rinse-off skin conditioning compositions comprising relatively low amounts of oil/emollient and relatively low amounts of aqueous phase stabilizer/structurant. Use of unsaturated fatty acid (or at least minimum amount of unsaturated fatty acid as percentage of total fatty acid) has been found to result in unexpectedly high hydration. In a second embodiment, use of branched fatty acid (at minimum amount branched as percentage of total) also results in superior hydration. Also mixtures of unsaturated and branched fatty acids can be used. | 03-05-2009 |
| 20090069424 | TGF-alpha expression inhibitors - An inhibitor against TGF-α expression and an inhibitor against transformation of a hepatitis and/or cirrhosis cell which comprise as an active ingredient a polyprenyl compound such as a polyprenyl carboxylic acid (for example, 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid). The inhibitor can be used as an inhibitor against onset, recurrence (second oncogenesis), and malignant alteration of carcinoma in a liver. | 03-12-2009 |
| 20090082444 | Compositions for the Treatment of Blood Disorders - The invention relates to compositions containing chemical compounds and compositions containing steel factor which stimulate the expression of hemoglobin or globin protein such as embryonic or fetal globin, or the proliferation of hemoglobin expressing and other cells. These compositions can be used to treat or prevent the symptoms associated with anemia, sickle cell diseases, thalassemia and other blood disorders. The invention also relates to methods for administering these compositions to patients and to medical aids for the treatment and prevention of blood and other disorders. | 03-26-2009 |
| 20090082445 | GOSSYPOL CO-CRYSTALS AND THE USE THEREOF - This invention relates to compositions comprising co-crystals of (−)-gossypol with a C | 03-26-2009 |
| 20090105339 | Curative drug for neurodegenerative diseases - A compound is prepared based on Formula 1: | 04-23-2009 |
| 20090118369 | Use of CIS-9, Trans-11 Isomer of Conjugated Lineoleic Acid - A composition and medicament comprising the cis-9, trans-11 isomer of conjugated linoleic acid for treating inflammatory diseases, including asthma, is provided. A method for inhibiting the proliferation of human or animal cells of the immune systems involved in an immune response including administering the cis-9, trans-11 isomer of conjugated linoleic acid to a patient is also provided. A nutritional, functional food, or dietary supplement including the cis-9, trans-11 isomer of conjugated linoleic acid is also provided. | 05-07-2009 |
| 20090118370 | METHOD OF TREATING CANCER USING DICHLOROACETATE - The invention relates to the use of dichloroacetate and chemical equivalents thereof for the treatment of cancer by inducing apoptosis or reversing apoptosis-resistance in a cell Preferably, the dosage is 10-100 mg/kg Preferably, sodium dichloroacetate is used. The dichloroacetate may optionally be given in combination with a pro-apoptotic agent and/or a chemotherapeutic agent Preferably, the cancers treated are non-small cell lung cancer, glioblastoma and breast carcinoma. | 05-07-2009 |
| 20090131521 | Aqueous retinoid and benzoyl peroxide gel - Embodiments of this invention relate to a composition containing both benzoyl peroxide and a retinoid. Additionally, it relates to the treatment of acne vulgaris by applying an aqueous gel comprising BPO and a retinoid. | 05-21-2009 |
| 20090137671 | METHODS OF TREATING METABOLIC DISORDERS - A method of increasing the insulin sensitivity of insulin resistant cells includes administering to the cells an amount of all-trans-retinoic acid effective to activate transcription factor perosixome proliferator-activated receptor (PPAR) β/δ of the cells. | 05-28-2009 |
| 20090149536 | 4-OXO-(ISO)TRETINOIN FOR THE TOPICAL TREATMENT OF SEVERE DERMATOLOGICAL DISORDERS - A method for the treatment of dermatological disorders wherein such treatment includes at least one of inhibiting lipogenesis in the skin and reducing the size of sebaceous glands, said treatment comprising the topical administration of a compound selected from 4-oxo-tretinoin, 4-oxo-isotretinoin and mixtures thereof to a patient in need thereof. The method of the invention is particularly advantageous for the topical treatment of severe acne and seborrhoea. | 06-11-2009 |
| 20090182048 | Compounds Useful For Treating Neurological Disorders - The invention relates to the use of compounds for the preparation of a medicament for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. The invention additionally relates to a pharmaceutical composition comprising compounds for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. A method for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration is also provided. | 07-16-2009 |
| 20090203782 | Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders - This invention relates to a method of treating certain disorders by administering a compound of the formula 1 | 08-13-2009 |
| 20090209643 | METHOD FOR MODULATING STEM CELL GROWTH - In one embodiment, provided is a composition comprising a prostaglandin compound for modulating stem cell proliferation and/or differentiation in a mammalian subject. In another embodiment, the instant application is a composition comprising a prostaglandin compound for, which comprises a prostaglandin compound for modulating proliferation and/or differentiation of stem cells of a mammalian subject, in which the stem cells are contacted directly or indirectly with the composition of the invention. | 08-20-2009 |
| 20090215893 | Parakeratosis inhibitor, pore-shrinking agent,or rough skin preventing/ameliorating agent, and external composition for skin - The invention provides a parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/amaliorating agent that has a function such as parakeratosis inhibition, pore shrinkage, or rough skin-inhibition/abatement, poses no safety problems such as sensory irritation, and is very safe, and to further provide an external composition for skin to which a compound having the above-mentioned function has been added. The parakeratosis inhibitor agent, pore-shrinking agent, or rough skin preventing/amaliorating agent comprises one, two, or more compounds selected from the group consisting of α-amino acid derivatives and salts thereof. The external composition for skin comprises the one, two, or more compounds selected from the group consisting of α-amino acid derivatives and salts thereof as the above-mentioned parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/amaliorating agent. | 08-27-2009 |
| 20090221704 | PROCESS FOR THE PREPARATION OF PEROXY ACIDS - The present invention relates to a process for the preparation of a solution comprising a first peroxy acid comprising performic acid and a second peroxy acid, said process comprising forming a carboxylic acid solution comprising a first carboxylic acid comprising formic acid, a second carboxylic acid and hydrogen peroxide, wherein the amount of formic acid is from 0.5 to 20% by weight of the amount of the second carboxylic acid, and allowing the components to react to form a solution comprising performic acid and said second peroxy acid, the amount of peroxy acids being at least 5% by weight. The invention also relates to a storable solution comprising performic acid and said second peroxy acid. The solution can be used as a disinfecting agent for controlling micro-organisms. | 09-03-2009 |
| 20090239948 | Enzymatic Production Of Peracids Using Perhydrolytic Enzymes - A process is provided to produce a concentrated aqueous peracid solution in situ using at least one enzyme having perhydrolase activity in the presence of hydrogen peroxide (at a concentration of at least 500 mM) under neutral to acidic reaction conditions from suitable carboxylic acid esters (including glycerides) and/or amides substrates. The concentrated peracid solution produced is sufficient for use in a variety of disinfection and/or bleaching applications. | 09-24-2009 |
| 20090247630 | DERMATOLOGICAL COMPOSITIONS COMPRISING AT LEAST ONE NAPHTHOIC ACID COMPOUND AND AT LEAST ONE FILM-FORMING AGENT AND TREATMENT OF KERATINIZATION DISORDERS THEREWITH - Topically applicable, reduced-irritant dermatological/cosmetic compositions useful for the prevention/treatment of a variety of keratinization disorders, for example acne vulgaris, contain at least one naphthoic acid compound essentially uniformly distributed therethrough and an amount of at least one hydrophilic film-forming agent, formulated into topically applicable, physiologically acceptable media therefor. | 10-01-2009 |
| 20090247631 | Enzymatic Production Of Peracids Using Perhydrolytic Enzymes - A process is provided to produce a concentrated aqueous peracid solution in situ using at least one enzyme having perhydrolase activity in the presence of hydrogen peroxide (at a concentration of at least 500 mM) under neutral to acidic reaction conditions from suitable carboxylic acid esters (including glycerides) and/or amides substrates. The concentrated peracid solution produced is sufficient for use in a variety of disinfection and/or bleaching applications. | 10-01-2009 |
| 20090247632 | DERMATOLOGICAL COMPOSITIONS AND METHODS - Dermatological compositions (methods of making and using) that include one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid. | 10-01-2009 |
| 20090253789 | Preventive/Remedy for Arteriosclerotic Disease and Method of Evaluating Therapeutic Procedure - There is provided an evaluation method of effect of a remedy or a therapeutic procedure for atherosclerosis directly or indirectly acting on a substance having a nature of exacerbating atherosclerosis (particularly, a protein) and being present in an atherosclerotic lesion to improve the atherosclerotic lesion, which comprises performing an evaluation by, regarding respective atherosclerotic lesion samples of a mammal origin collected from an administration- or application-group of the remedy or therapeutic procedure, and from a non-administration- or non-application-group, comparing a value of one group corresponding to strength of an atherosclerosis-exacerbating activity of the substance (for example, a pharmacological activity such as an enzyme activity) present in the sample and corrected by an amount of a correction marker in the atherosclerotic lesion, with that of the other group, said amount of the correction maker varying correlating with an amount of the substance in the atherosclerotic lesion and being not influenced by the remedy or therapeutic procedure to be evaluated. | 10-08-2009 |
| 20090253790 | Dairy Composition with Probiotics and Anti-Microbial System - Dairy compositions are provided having a high pH, of about 4.8 to about 6.2, comprising desirable probiotic cultures as well as an anti-microbial system for inhibiting undesirable pathogenic and/or spoilage microbial growth without significantly reducing the beneficial effect of the probiotic cultures. | 10-08-2009 |
| 20090264526 | Natural ligand of G protein coupled receptor RCC356 and uses thereof - The invention relates to the identification of isovaleric acid as a natural ligand of the RCC356 G-protein coupled receptor (GPCR). The invention encompasses the use of the interaction of RCC356 polypeptides and isovaleric acid as the basis of screening assays for agents that modulate the activity of the RCC356 receptor. The invention also encompasses diagnostic and other assays performed based upon the RCC356/isovaleric acid interaction, as well as kits for performing diagnostic and screening assays. | 10-22-2009 |
| 20090264527 | METHOD FOR STABILIZING RETINOIC ACID, RETINOIC ACID CONTAINING COMPOSITION, AND METHOD OF USING A RETINOIC ACID CONTAINING COMPOSITION - A method for stabilizing retinoic acid is provided. The method includes a step of mixing retinoic acid with a hydrophobic polymer/hydrophilic polymer adduct in the presence of an oxygen containing atmosphere to form a retinoic acid containing composition. The hydrophobic polymer/hydrophilic polymer adduct comprises a poly(vinylpyrrolidone/alkylene) polymer and a polymer comprising repeating carboxylic acid groups, hydroxyl groups, or a mixture of carboxylic acid groups and hydroxyl groups. A retinoic acid containing composition and a method of using a retinoic acid containing composition are provided. | 10-22-2009 |
| 20090270501 | COMPOSITION AND METHOD FOR INCREASING THE ANABOLIC STATE OF MUSCLE CELLS - A nutritional supplement comprising at least a therapeutically effective amount of ethyl pyruvate and a therapeutically effective amount of at least one α-hydroxy branched-chain amino acid metabolite is provided by the present invention. The ingredients of the present nutritional supplement substantially simultaneously act to induce a anabolically-favorable state for muscle by substantially simultaneously maintaining blood and muscle physiological pH levels as well as increasing cellular concentrations of branched-chain amino acids. Both a composition and a method are provided by the present disclosure. | 10-29-2009 |
| 20090275656 | Medicinal Compositions of Salts, Chelates and/or Free Acids of Alpha Hydroxyl Organic Acids and Related Processes and Methods - Processes are described for the production of an isolated medicinal composition for administration to mammals which comprises an effective amount of a free acid, salt or chelate of at least one naturally occurring form of an alpha hydroxyl organic acid comprising combining at least one naturally occurring form of an alpha hydroxy organic acid with an amount of base in an aqueous solution, wherein a total content of alpha hydroxyl organic acids amounts to between about 0.5% and about 35% w/w of the solution, for a time to hydrolyse substantially all forms of alpha hydroxyl organic acids present, neutralizing the solution to a pH between about 6.9 and about 7.6 to yield a free acid, salt or chelate of free acids of substantially all naturally occurring forms of alpha hydroxyl organic acids, and optionally lyophilizing the solution to produce an isolated medicinal composition. Compositions produced by these processes are disclosed and claimed. Method are described of enhancing DNA repair, enhancing an immune response, controlling inflammation, or inhibiting the progress of a tumor, comprising administering an effective amount of a composition produced by the processes described herein. | 11-05-2009 |
| 20090298938 | USE OF SEMI SYNTHETIC ANALOGUES OF BOSWELLIC ACIDS FOR ANTICANCER ACTIVITY - The present invention relates to use of compounds of general formula 1 for anticancerous activity, wherein the said compound being derived semi-synthetically from natural triterpenoic acids known as boswellic acids by the induction of apoptosis thereof cytotoxicity and anti-cancer activity displayed by semi-synthetic analogues of natural triterpenes, known as Boswellic acids. These compounds may be used for the treatment of cancer, alone or in combination with pharmaceutically acceptable or other carriers, displaying cytotoxicity and anti-cancer activity for colon, prostrate, liver, breast, central nervous system (CNS), leukemia and malignancy of other tissues, including ascites and solid tumors. The cancer cell death is mediated by induction of apoptosis and inhibition of cell proliferation at specific doses. | 12-03-2009 |
| 20090298939 | Method of preparation and composition of a water soluble extract of the bioactive component of the plant species Uncaria for enhancing immune, anti-inflammatory, anti-tumor and DNA repair processes of warm blooded animals - The disclosure provides a method for isolating the bioactive component of the water-soluble extract of | 12-03-2009 |
| 20090298940 | All Natural Antifungal And Antimicrobial Composition And Method Thereof - In accordance with the present invention, there is provided a novel all natural antifungal composition and method. There is further provided a novel all natural antibiotic and antimicrobial composition and method. There is provided an antifungal and/or antimicrobial composition and method that may be used to treat conditions caused by gram negative bacteria, viruses and fungi, especially molds and mycocytes, with a composition comprising potassium sorbate, lecithin, cellulose, and wax. There is provided a composition and method for administration directly to dermal, oral, gastrointestinal and/or nasal tissues that are affected by molds and mycocytes. | 12-03-2009 |
| 20090298941 | ANTI-ADIPOCYTE FATTY ACID-BINDING PROTEIN (AP2), ANTI-FLAP AND ANTI-CYSLT1 RECEPTOR HERBAL COMPOSITIONS - Herbal compositions having anti-adipocyte fatty acid-binding protein (aP2), anti-5-lipoxygenase-activating protein (FLAP) and anti-Cysteinyl Leukotriene (CysLT)-1 receptor expression activity contain an extract of | 12-03-2009 |
| 20090312420 | Production Of Peracids Using An Enzyme Having Perhydrolysis Activity - A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided. | 12-17-2009 |
| 20100016429 | Enzymatic Production Of Peracids Using Perhydrolytic Enzymes - A process is provided to produce a concentrated aqueous peracid solution in situ using at least one enzyme having perhydrolase activity in the presence of hydrogen peroxide (at a concentration of at least 500 mM) under neutral to acidic reaction conditions from suitable carboxylic acid esters (including glycerides) and/or amides substrates. The concentrated peracid solution produced is sufficient for use in a variety of disinfection and/or bleaching applications. | 01-21-2010 |
| 20100022644 | PEROXYCARBOXYLIC ACID COMPOSITIONS WITH REDUCED ODOR - The present invention relates to compositions of peroxycarboxylic acid that have reduced odor compared to conventional peroxycarboxylic acid compositions, methods employing these reduced-odor compositions, and methods of making these compositions. Typically, the reduced-odor compositions include an amine oxide surfactant. | 01-28-2010 |
| 20100041752 | Production of peracids using an enzyme having perhydrolysis activity - A method is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity derived from | 02-18-2010 |
| 20100041753 | INHIBITION OF BIOFILM FORMATION - The present invention relates to compositions and methods for reducing or inhibiting biofilm comprising modulating expression of a cysB gene in a cell. The invention also provides methods for modulating the expression of a cysB, cysD, cysI, cysJ, cysK, and ybiK. The invention further provides methods for identifying gene(s) involved in biofilm formation and for identifying biofilm inhibitors. | 02-18-2010 |
| 20100048703 | Hair care product - A substance having a testosterone 5α-reductase inhibiting action, a hair papilla cell growth promoting action, a fibroblast growth factor-7 production promoting action, a vascular endothelial growth factor production promoting action or a bone morphogenetic protein-2 production promoting action, and a hair care product having this substance blended therein. A hair growth tonic, a testosterone 5α-reductase inhibitor, a hair papilla cell growth promoter, a fibroblast growth factor-7 production promoter, a vascular endothelial growth factor production promoter and a bone morphogenetic protein-2 production promoter each having this substance, such as corosolic acid, as an active ingredient thereof. | 02-25-2010 |
| 20100056629 | RETROVIRUS-INFECTION INHIBITOR - An infection inhibitor of retrovirus, particularly human immunodeficiency virus, comprising, as an active ingredient, at least one compound selected from the group consisting of a compound represented by the formula (I) (GGA) or a salt thereof, a compound represented by the formula (II) (NIK-333) or a salt thereof, and derivatives thereof. | 03-04-2010 |
| 20100056630 | COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF FIRE BLIGHT - The invention relates to an agent for treating and/or preventing fire blight, particularly present in wood and fruit trees, comprising formic acid and/or a salt of formic acid, particularly calcium formiate as an active component. Further disclosed is the use of formic acid and/or a salt of formic acid, particularly calcium formiate as an active component in herbicides, particularly for treating and/or preventing fire blight, and the use of formic acid and/or a salt of formic acid, particularly calcium formiate, for the production of an agent for treating and/or preventing fire blight. | 03-04-2010 |
| 20100056631 | ANTIALLERGENIC COMPOSITION - An antiallergenic composition comprising 3-hydroxybutyric acid and/or a salt thereof. The antiallergenic composition is safe. | 03-04-2010 |
| 20100076081 | METHOD FOR PRODUCING SALT OF 4-SULFINYLAMINO-1-CYCLOHEXANECARBOXYLIC ACID - Disclosed is a salt of trans-4-sulfinylamino-1-cyclohexanecarboxylic acid. Also disclosed is a method for producing a salt of trans-4-sulfinylamino-1-cyclohexanecarboxylic acid. | 03-25-2010 |
| 20100076082 | New Cleaning, Descaling and Disinfecting Composition for Dialysis Generators - Composition comprising, per 100% of its mass, essentially: from 0.50% by mass to 1.50% by mass of peracetic acid, from 3.00% by mass to 15.00% by mass of hydrogen peroxide, from 3.00% by mass to 15.00% by mass of acetic acid, from 0.10% by mass to 1.00% by mass of concentrated nitric acid, from 0.001% by mass to 0.20% by mass of nonionic surfactant, from 0.01% by mass to 0.10% by mass of amine oxide, from 0.01% by mass to 0.20% by mass of stabilizer, and water to make up to 100% by mass; use thereof for cleaning, descaling and disinfecting dialysis equipment between two successive dialysis sessions, without additional treatment other than rinsing of said dialysis equipment with osmosed water; methods for the use thereof. | 03-25-2010 |
| 20100081716 | PROCESS FOR PRODUCTION OF ETHER CARBOXYLATES - The present invention relates to a process for producing an ether carboxylate which includes the steps of (1) reacting an aliphatic monohydric alcohol with an alkylene oxide in the presence of an alkali catalyst; (2) neutralizing a reaction solution obtained in the step (1) with an acid such as hydroxycarboxylic acids to obtain an ether alcohol; and (3-1) reacting the obtained ether alcohol with a monohalogenofatty acid or a salt thereof and an alkali metal hydroxide, or (3-2) subjecting the obtained ether alcohol to catalytic oxidation reaction in the presence of a catalyst. The obtained ether carboxylate has a less odor and a high quality and is therefore suitably used in the applications such as cosmetics and toiletries. | 04-01-2010 |
| 20100087528 | ENZYMATIC PERACID PRODUCTION USING A COSOLVENT - Disclosed herein are two-component enzymatic peracid generation systems and methods of using such systems wherein the first component comprises a formulation of at least one enzyme catalyst having perhydrolysis activity, a carboxylic acid ester substrate, and a cosolvent and wherein the second component comprises a source of peroxygen in water. The two components are combined to produce an aqueous peracid formulation useful as, e.g., a disinfecting or bleaching agent. Specifically, organic cosolvents are used to control the viscosity of a substrate-containing component and to enhance the solubility of the substrate in an aqueous reaction formulation without causing substantial loss of perhydrolytic activity of the enzyme catalyst. | 04-08-2010 |
| 20100087529 | PERHYDROLASES FOR ENZYMATIC PERACID GENERATION - Disclosed herein are variants enzymes that are structurally classified as CE-7 enzymes and have perhydrolysis activity. Also disclosed herein is a process for producing peroxycarboxylic acids from carboxylic acid esters using the aforementioned variant enzymes as well as methods and compositions comprising the variant enzymes. Further, disinfectant formulations comprising the peroxycarboxylic acids produced by the processes described herein are provided. | 04-08-2010 |
| 20100087530 | METHODS FOR WASHING POULTRY DURING PROCESSING WITH MEDIUM CHAIN PEROXYCARBOXYLIC ACID COMPOSITIONS - The present invention relates to methods for reducing microbial contamination on poultry, or on surfaces used in processing poultry, employing compositions including medium chain peroxycarboxylic acid, and to the compositions. The methods include applying a medium chain peroxycarboxylic acid composition to poultry or to the surfaces. | 04-08-2010 |
| 20100093860 | HYDROXYBUTYRATE AND POLY-HYDROXYBUTYRATE AS COMPONENTS OF ANIMAL FEED OR FEED ADDITIVES - This invention relates to the use of hydroxybutyrate and poly hydroxybutyrate as components of animal feed or feed additives, as well as to compositions, feed additives and feed containing them. The inventors surprisingly found that hydroxybutyrate and poly-hydroxybutyrate, preferably 3-hydroxybutyrate and poly-3-hydroxybutyrate, have a great potential for use in animal feed for modulation of the gut flora. More precisely, it has been found that poly-3-hydroxybutyrate or a microbial strain capable for producing poly-3-hydroxybutyrate can be used as a potential growth promoter or gut flora modulator by releasing SCFA, preferably 3-hydroxy butyric acid, in the gut micro flora. Further, the inventors found that 3-hydroxybutyrate and poly-3-hydroxybutyrate have a great potential for suppressing or inhibiting pathogenic bacteria in the gastro intestinal tract, e.g. have a antimicrobial activity against strains of | 04-15-2010 |
| 20100093861 | TREATMENT OF INSULIN RESISTANCE OR DISEASES ASSOCIATED WITH INSULIN RESISTANCE - The present invention relates to the use of a substance with the core structure of formula (I), or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the manufacture of a composition for the treatment of insulin resistance or diseases associated with insulin resistance, preferably in human subject in a daily dosage in a range of from about 5 mg to about 1500 mg. The invention furthermore relates to a method of treating insulin resistance or diseases associated with insulin resistance in a mammal, said method comprises administering to said mamma, preferably a human subject, a substance with the core structure of formula (I), preferably in a daily dosage in a range from about 5 mg to about 1500 mg. The substance is preferably isosteviol or steviol, or pharmaceutically acceptable salts, solvates or prodrugs thereof. Examples of diseases associated with insulin resistance are e.g. type 2 diabetes mellitus, insulin resistance syndrome, impaired glucose tolerance, the metabolic syndrome, hyperglycemia, hyperinsulinemia, arteriosclerosis, hypercholesterolemia, hypertriglyceridemia, hyperlipidemia, dyslipidemia, obesity, central obesity, polycystic ovarian syndrome, hypercoagulability, hypertension, microalbuminuria, or any combinations thereof. | 04-15-2010 |
| 20100093862 | POTENTIATION OF CELLULAR IMMUNITY USING HISTONE DEACETYLASE (HDAC) INHIBITORS. - [Technical Problem] The present invention provides an enhancer of cellular immunity, and provides applications to carcinogenesis or preventive therapy against cancer recurrence, immunotherapy for cancer, treatment for pathogenic microorganism infection, and the like. | 04-15-2010 |
| 20100099763 | TRITERPENE COMPOUNDS WHICH ARE EFFECTIVE ON IMPROVEMENT OF BRAIN FUNCTION - The present invention relates to the triterpene compounds improving in brain functions. In particular, the present invention relates to a novel use of the triterpene compounds represented by the Formula 1 for improving decreased memory and a pharmaceutical composition for improving brain functions comprising the triterpene compounds represented by the Formula 1. | 04-22-2010 |
| 20100120913 | RESIN CATALYZED AND STABILIZED PERACID COMPOSITIONS AND ASSOCIATED METHODS - Methods, compositions, and system for making and stabilizing peracids in peracid-containing compositions are provided. The method of making can include the contacting of a cationic exchange resin with a carboxylic acid and hydrogen peroxide containing solution and maintaining the peracid in contact with the solution for a period of at least 24 hours to form a peracid. The solution to cationic exchange resin weight ratio used in the method is at least 10:1 w/w. The method of stabilizing can similarly include the maintaining the contact between the peracid-containing composition in contact with the cationic exchange resin during the storage of the peracid-containing composition. The methods and systems are particularly useful for peracid-containing disinfectant compositions. | 05-13-2010 |
| 20100125104 | Alpha-Keto Peracids and Methods For Producing and Using the Same - The present invention provides α-keto peracids and methods for producing and using the same. In particular, α-keto peracids are useful as antimicrobial agents. | 05-20-2010 |
| 20100144877 | Synergistic Enhancement of Calcium Propionate - A novel composition comprised of a monocarboxylic fatty acid synergistically enhanced with a dual quaternary ammonium compound to provide immediate fungal and sporicidal destruction with long term residual resistance. | 06-10-2010 |
| 20100152292 | Production of Peracids Using An Enzyme Having Perhydrolysis Activity - A method is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity derived from | 06-17-2010 |
| 20100168233 | TERBINAFINE FORMULATION - The present invention provides a pharmaceutical composition comprising as the active agent a terbinafine compound, water, and at least one water-soluble or water-miscible nonionic surfactant, wherein the terbinafine compound has at least one form selected from the group consisting of free base form, acid addition salt form, ionic form, and combinations thereof; and wherein substantially no alcohol is present. | 07-01-2010 |
| 20100168234 | PRODUCTION OF PERACIDS USING AN ENZYME HAVING PERHYDROLYSIS ACTIVITY - A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided. | 07-01-2010 |
| 20100168235 | PRODUCTION OF PERACIDS USING AN ENZYME HAVING PERHYDROLYSIS ACTIVITY - A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided. | 07-01-2010 |
| 20100168236 | PRODUCTION OF PERACIDS USING AN ENZYME HAVING PERHYDROLYSIS ACTIVITY - A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided. | 07-01-2010 |
| 20100168237 | PRODUCTION OF PERACIDS USING AN ENZYME HAVING PERHYDROLYSIS ACTIVITY - A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided. | 07-01-2010 |
| 20100179219 | Plane Tree Cream, Method for the Production Thereof and Use - In order to prevent betulinic acid from crystallizing in a galenic preparation containing water, a plane tree cream in the form of a stable emulsion containing oil and water is proposed, which is characterized by a content of 2 to 10% by weight of a plane tree extract obtained from the bark of plane trees, 0.1 to 9.9% by weight of glycerol, 0.1 to 1.9% by weight of a gelatinizing agent and 5 to 15% by weight of a preservative. The plane tree extract used is obtained by extracting plane tree bark with a low alkanol. The plane tree cream is used for the topical treatment of the skin, including the mucous membranes. | 07-15-2010 |
| 20100184859 | MEDICAMENT HAVING PROMOTING ACTION ON HEPATOCYTE PROLIFERATION - A medicament for promoting proliferation of hepatocytes and liver regeneration, which comprises a polyprenyl compound such as 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid as an active ingredient. | 07-22-2010 |
| 20100184860 | Novel Carboxylic Acid and Antidepressant Composition Containing the Same as Active Ingredient - The present invention provides a novel compound and antidepressant composition that can be effectively used for improving depressed mood and depressed state, particularly for depressed mood and depressed state in menopausal women. The compound of the present invention is represented by the following formula (1): | 07-22-2010 |
| 20100190858 | Pharmaceutical Formulations Containing Lipoic Acid Derivatives - Pharmaceutical formulations containing lipoic acid derivatives and ion pairs thereof are described. The pharmaceutical formulations are useful in the treatment of medical disorders, such as cancer. | 07-29-2010 |
| 20100197786 | Insect-repellent formulations - An insect repellent aqueous formulation comprising a combination of at least two essential oils, citrus peel tincture, and vinegar. | 08-05-2010 |
| 20100204325 | VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF - Biocompatible, bioerodible, sustained release drug delivery system formulated as implants, microspheres and high viscosity hyaluronic acid solutions comprise valproic acid as therapeutic agent and a biodegradable polymer, the system being effective, when placed intraocular (such as into the subtenon space or into the vitreous) to treat a retinal disease or condition. | 08-12-2010 |
| 20100240751 | Methods - A perfluoroctanoic acid or a salt or an ester thereof; perfluorosuberic acid, perfluoroheptanoic acid, perfluorohexanoic acid, perfluoropentanoic acid, perfluorobutanoic acid or perfluoropropionic acid or a salt or an ester any thereof; or perfluoroctane are useful in treating diabetes, obesity, hypercholesterolaemia, hyperlipidaemia, cancer, inflammation or other conditions in which modulation of lipid or eicosanoid status or function may be desirable. | 09-23-2010 |
| 20100240752 | Aqueous Acidic Hard Surface Cleaning and Disinfecting Compositions - A highly aqueous liquid acidic hard surface treatment composition having a pH of about 3.5 or less which necessarily comprises:
| 09-23-2010 |
| 20100249231 | HSP90 Inhibitors of Protein-Protein Interaction HSP90 Chaperone Complexes and Therapeutic Uses Thereof - A novel Hsp90 inhibitor that disrupts protein-protein interaction in a Hsp90 superchaperone complex without blocking ATP binding and methods for treating diseases such as pancreatic cancer are disclosed. | 09-30-2010 |
| 20100261792 | Alpha-Keto Alkylperacids and Methods For Producing and Using the Same - The present invention provides α-keto alkylperacids and methods for producing and using the same. In particular, α-keto alkylperacids are useful as antimicrobial agents. | 10-14-2010 |
| 20100280114 | Primers and primer sets for use in methods to detect the presence of acidovorax avenae subsp. citrulli - The present invention relates to oligonucleotide primers and primer sets that can be used to identify the bacterial pathogen | 11-04-2010 |
| 20100331412 | Two container skin care product - A skin product for improving the skin includes a first container containing a first product, the first product including alpha hydroxy acid, and second container containing a second product, the second product including a combination of humectants, moisturizers and an AHA (glycolic acid) formulation. | 12-30-2010 |
| 20100331413 | Therapeutic Formulations Based on Asiatic Acid and Selected Salts Thereof - A highly pure asiaticoside and a pharmaceutical grade asiatic acid can be prepared, along with salts of asiatic acid, for use in formulating therapeutic compositions that are suitable for treating arthritis, psoriasis and other inflammatory diseases, as well as pulmonary fibrosis, diabetic nephropathy, and other fibrotic diseases. | 12-30-2010 |
| 20110028549 | USE OF A MONOTERPENE TO TREAT OR PREVENT STRESS - The present invention relates to the use of a monoterpene for the prevention, alleviation or treatment of a pathological or non-pathological stress condition of an individual. | 02-03-2011 |
| 20110028550 | COMPOSITIONS AND METHODS FOR CONTROL OF LISTERIA MONOCYTOGENES - The present invention relates to methods for inhibiting the growth of pathogenic microbes in food products. In an embodiment the invention is a preservative composition including lactic acid or a salt thereof, acetic acid or a salt thereof, and propionic acid or a salt thereof. In an embodiment, the invention is a food product including lactic acid or a salt thereof, acetic acid or a salt thereof, and propionic acid or a salt thereof. In an embodiment, the invention includes a method of making a food product including adding an antimicrobial preservative composition to a composition comprising a meat, the antimicrobial preservative composition comprising lactic acid or a salt thereof, propionic acid or a salt thereof, and acetic acid or a salt thereof. Other embodiments are also included herein. | 02-03-2011 |
| 20110028551 | NOVEL PROCESS FOR THE PREPARATION OF SODIUM GAMMA-HYDROXYBUTYRATE - The present invention is directed to a process for the preparation of the saponification products of lactones, preferably three- to eight-membered lactones. The present invention is also directed to a process for the preparation of compounds having general formula (I): wherein M is selected from the group consisting of cationic species, preferably metal cations (even more preferably Na), from a compound having the formula (II): comprising reacting a compound having formula (II) with a suitable hydroxide salt (M-OH) (III) such as, preferably, sodium hydroxide, in an aqueous medium. The reaction preferably utilizes a continuous process method for the substantial consumption of reagent and continuous, semi-continuous, and/or batch-wise processing for final consumption of reagent. | 02-03-2011 |
| 20110039929 | MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient. | 02-17-2011 |
| 20110054025 | USE OF A PENTACYCLIC TRITERPENE IN A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MULTIPLE SCLEROSIS - Oleanolic acid (3β-hiydroxyolean-12-en-28-oic acid) is a pentacyclic triterpene occurring in a large number of medicinal plants. The present invention is directed to the pharmacological application of the oleanolic acid, alone or in combination with other substances, in the treatment or prophylaxis of neurodegenerative diseases such as multiple sclerosis. The inventors have found that oleanolic acid, intraperitoneally administered once daily, reduces significantly the immuno-inflammatory and neurological symptoms associated with the experimental autoimmune encephalomyelitis, an experimental model of multiple sclerosis, delaying the onset and reducing the progression of the disease. | 03-03-2011 |
| 20110060044 | ALIPHATIC ACID-CONTAINING N-HALOGENATED AMINO ACID FORMULATIONS - The present invention relates to methods for treating an infected tissue comprising treating the infected tissue with a formulation comprising a N-halogenated amino acid and an aliphatic acid. This specification also discloses methods for improving the antimicrobial activity of a formulation comprising a N-halogenated amino acid, the method comprising adding an aliphatic acid to said formulation. | 03-10-2011 |
| 20110065792 | NOVEL SUBSTANCES ANALOGOUS TO MK8383 AND AGRICULTURAL AND HORTICULTURAL DISEASE CONTROL AGENTS - An objective of the present invention is to provide agricultural and horticultural disease control agents that have potent control effect against plant diseases and, at the same time, have high photostability. The agricultural and horticultural disease control agents comprise a novel substance analogous to MK8383 as an active ingredient. | 03-17-2011 |
| 20110071223 | BODY COSMETICS FOR WETTED SKIN - A body cosmetic for application to wetted skin after bathing, and the like, which provide high moisturizing effects, spread well to all over the body, and are easy to apply. | 03-24-2011 |
| 20110086918 | Broad Spectrum Preservation Blends - A composition having effective broad spectrum preservation activity comprising benzyl alcohol, salicylic acid, sorbic acid and a compound selected from the group consisting of 1,3-propanediol, glycerin and combinations thereof. | 04-14-2011 |
| 20110098357 | VAGINAL SUPPOSITORY COMPRISING LACTIC ACID - The present invention relates to a vaginal suppository comprising an inert vehicle and lactic acid or a salt thereof for the treatment and/or prophylaxis of disorders in the urogenital tract. It also relates to the use of such a suppository for the production of a medicament for the treatment and/or prophylaxis of disorders in the urogenital tract as well as to a method for the treatment and/or prophylaxis of disorders in the urogenital tract. | 04-28-2011 |
| 20110105611 | USE OF MASLINIC ACID FOR THE TREATMENT OF PATHOLOGIES AND THEIR SYMPTOMS THROUGH THE INHIBITION OF COX-2 - The invention relates to the use of maslinic acid or natural, synthetic or semi-synthetic maslinic-rich mixtures or of a composition containing said acid for the treatment of pathological processes associated with COX-2 activation, intended, inter alia, for the symptomatic and/or regenerative treatment of arthrosis, rheumatoid arthritis, fibromyalgia, sciatica and other articular disorders that are difficult to diagnose. The invention also relates to the topical administration thereof. | 05-05-2011 |
| 20110136907 | PERHYDROLASE PROVIDING IMPROVED PERACID STABILITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 06-09-2011 |
| 20110136908 | PERHYDROLASE PROVIDING IMPROVED PERACID STABILITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 06-09-2011 |
| 20110152368 | PERHYDROLASE PROVIDING IMPROVED PERACID STABILITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 06-23-2011 |
| 20110152369 | PERHYDROLASE PROVIDING IMPROVED PERACID STABILITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 06-23-2011 |
| 20110152370 | PERHYDROLASE PROVIDING IMPROVED PERACID STABILITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 06-23-2011 |
| 20110178175 | METHOD FOR PRODUCING MECHANICALLY ACTIVATED AMORPHOUS AND AMORPHOCRYSTALLINE COMPOUNDS OF GLUCONIC ACID CALCIUM SALT - The invention relates to the creation of mechanically activated amorphous and amorphocrystalline compounds and compositions of a gluconic acid calcium salt, pharmaceutical preparations based thereon, a method for producing same and use for treatment of a wide range of diseases caused by disorders of calcium metabolism in an organism. A concept of the invention, as being claimed and as set forth in the application, consists in that the crystalline gluconic acid calcium salt or its compound with excipients is treated in grinding activator devices either up to the input specific energy value of not greater than 10.4 kJ/g and achieving an amorphocrystalline state or up to the input specific energy value of no less than 10.5 kJ/g and achieving an amorphous state. The obtainable agents are assessed by means of X-ray diffraction, IR, NMR, EPR spectroscopy, mass- or chromato-mass-spectrometry, and a differential thermal analysis. The mechanically activated amorphous and amorphocrystalline compounds and compositions are used as an active principle for preparing pharmaceutical preparations used for therapeutic, therapeutic-preventive and hygienic purposes. The pharmaceutical preparations comprising a therapeutically effective amount of active ingredient are used perorally 1-6 times daily, in dosages of 0.2-6 g, a course of at least 1 month. The invention can be used in medical and food industries in the production of biologically active agents, therapeutic-prophylactic means, medicinals and in practical medicine in treatment of acute osseous, dental and other diseases related to disorders of calcium metabolism in the organism. | 07-21-2011 |
| 20110263706 | METHOD FOR ENHANCING THE DNA REPAIR PROCESS, TREATING DISORDERS ASSOCIATED WITH THE DNA REPAIR PROCESS, ENHANCING ANTITUMOR RESPONSE AND TREATING DISORDERS ASSOCIATED WITH ANTI-TUMOR RESPONSE IN MAMMALS BY ADMINISTERING PRUIFIED QUINIC ACID AND/OR CARBOXY ALKYL ESTER - The disclosure provides a method for isolating the bioactive component of the water-soluble extract of | 10-27-2011 |
| 20110263707 | MOSQUITO REPELLENT - The present invention relates to a mosquito repellent comprises at least one or more selected from the group consisting of neric acid and derivatives thereof in an effective amount to repel mosquito. | 10-27-2011 |
| 20110288172 | DERMATOLOGICAL COMPOSITIONS AND METHODS - Dermatological compositions (methods of making and using) that include one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid. | 11-24-2011 |
| 20110306667 | Stabilization Of Perhydrolases - Disclosed herein is a method for stabilization of the perhydrolase activity of the CE-7 esterase in a formulation with a carboxylic acid ester that employs the addition of a buffering agent, substantially undissolved, to the mixture of the CE-7 esterase and the carboxylic acid ester. Further, disinfectant and laundry care formulations comprising the peracids produced by the processes described herein are provided. | 12-15-2011 |
| 20120016025 | PERHYDROLASES FOR ENZYMATIC PERACID GENERATION - Disclosed herein are variants enzymes that are structurally classified as CE-7 enzymes and have perhydrolysis activity. Also disclosed herein is a process for producing peroxycarboxylic acids from carboxylic acid esters using the aforementioned variant enzymes as well as methods and compositions comprising the variant enzymes. Further, disinfectant formulations comprising the peroxycarboxylic acids produced by the processes described herein are provided. | 01-19-2012 |
| 20120059059 | METHOD FOR INHIBITING ACTIVITY AND/OR EXPRESSION OF MATRIX METALLOPROTEINASE, INHIBITING PHOSPHORYLATION OF MITOGEN-ACTIVATED PROTEIN KINASE, AND/OR PROMOTING EXPRESSION OF COLLAGEN USING TORMENTIC ACID - A method for inhibiting the activity of matrix metalloproteinase (MMP), inhibiting the expression of matrix metalloproteinase, inhibiting the phosphorylation of mitogen-activated protein kinase (MAPK), and/or promoting the expression of collagen in a mammal is provided. The method comprises administrating to the mammal an effective amount of an active component selected from a group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable ester of the compound, and combinations thereof: | 03-08-2012 |
| 20120059060 | VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF - Biocompatible, bioerodible, sustained release drug delivery system formulated as implants, microspheres and high viscosity hyaluronic acid solutions comprise valproic acid as therapeutic agent and a biodegradable polymer, the system being effective, when placed intraocular (such as into the subtenon space or into the vitreous) to treat a retinal disease or condition. | 03-08-2012 |
| 20120065262 | COMPOSITION FOR PREVENTING HAIR LOSS OR FOR STIMULATING HAIR GROWTH - Provided is a composition for preventing hair loss or promoting hair growth including valproic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The composition may be applied to various industrial fields, including pharmaceutical, cosmetic and beauty aid industries. | 03-15-2012 |
| 20120071554 | DEUTERATED 2-PROPYLPENTANOIC ACID COMPOUNDS - Described herein are novel analogs of 2-propylpentanoic acid, pharmaceutical compositions comprising the same, and methods of using the same for the treatment of diseases or conditions that are beneficially treated by administering a GABAAergic transmission enhancer and/or a histone deacetylase (HDAC) inhibitor. | 03-22-2012 |
| 20120071555 | COMPOSITIONS OF ABSCISIC ACID FOR ANIMAL HEALTH - The invention relates to compositions comprising abscisic acid, and/or salts, derivatives and analogs thereof, and methods of using the same for improving the health and offspring mortality of animals. | 03-22-2012 |
| 20120071556 | PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS OF ABSCISIC ACID - The invention relates to compositions comprising abscisic acid, and/or salts, derivatives and analogs thereof, and methods of pharmaceutical and/or nutraceutical use. | 03-22-2012 |
| 20120071557 | ANIMAL FEED COMPOSITIONS OF ABSCISIC ACID - The invention relates to compositions comprising abscisic acid, and/or salts, and derivatives thereof, and methods of using the same for improving the health, growth, and feed efficiency of livestock and fish as well as the quantity of meat produced in livestock in particular. | 03-22-2012 |
| 20120101161 | FATTY ACID ANALOGUES FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISORDERS - The present invention relates to fatty acid analogues of the general formula R | 04-26-2012 |
| 20120115951 | PROTECTIVE ACTION OF SEROFENDIC ACID ON CARDIAC MUSCLE - A cardiac myocyte protective agent, comprising a compound represented by the formula (Ia) below, a pharmaceutically acceptable salt thereof, or a solvate thereof: | 05-10-2012 |
| 20120115952 | METHOD FOR IMPROVING THE SENSORY PROPERTIES AND RESISTANCE OF FOOD AND DRINK PRODUCTS TO MICRO-ORGANISMS - A method for improving the sensory properties and resistance of food and drink products, especially uncured meat products, to various kinds of micro-organisms and in particular food spoilage and food poisoning bacteria includes contacting the food or drink product with a composition comprising alkali metal salts having as anions propionate and a co-anion selected from lactate, acetate, and combinations thereof, and as cations potassium and hydrogen, wherein the weight-based ratio of lactate/propionate is in the range of 0 to 20 and the weight-based ratio of acetate/propionate is in the range of 0.05 to 3.5. | 05-10-2012 |
| 20120115953 | Self-Neutralizing Acid Peel for Dermatologic Use - A dermatologic peel comprising alpha hydroxyl acid and metal hydroxide nanocomplexes as neutralizing agents to continually reduce the activity of the system when the acid and neutralizer components are mixed. For example, a 30% glycolic acid gel mixed with a fluidized magaldrate neutralizer can be applied to the skin and will self-neutralize to a skin-compatible pH within a few minutes, effectively exfoliating the skin without a separate neutralization step. The peel is advantageously applied from a two-component system that mixes the components. | 05-10-2012 |
| 20120122979 | CONTROL OF ENZYMATIC PERACID GENERATION - A process is provided for producing target concentrations of peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity under conditions where control of reaction pH by selection of buffer concentration and concentration of perhydrolase and reactants produces a targeted concentration of peroxycarboxylic acids. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided, as are corresponding methods of use. | 05-17-2012 |
| 20120129935 | NUTRITION WITH LIPIDS AND NON-DIGESTIBLE SACCHARIDES - The invention relates to a liquid nutrition comprising short chain fatty acyl chains and a non-digestible, fermentable saccharide. The composition is particular suitable for use as an infant nutrition. The composition is also suitable for treatment and/or prevention of gut barrier related disorders. | 05-24-2012 |
| 20120157527 | COSMETIC USE OF A JASMONIC ACID DERIVATIVE FOR TREATING THE HAIR AND THE SCALP - The present invention relates to the cosmetic use of jasmonic acid derivatives of formula (I) | 06-21-2012 |
| 20120165407 | STRATEGY FOR ON-SITE IN SITU GENERATION OF OXIDIZING COMPOUNDS AND APPLICATION OF THE OXIDIZING COMPOUND FOR MICROBIAL CONTROL - The invention provides a method of controlling biological fouling of water containing items. The method involves combining at least two reactants, a peroxygen source and an acyl group donor to form peracetic acid. Because the peracetic acid can be made in situ, the entire sum of its short lifespan can be used controlling biocidal fouling and storage and transport is simplified. The invention further facilitates the ease of controlling biocidal fouling by allowing the injection of the biocidal agent in liquid form, in a non-acidic environment, and without the need for any halogen. This allows the inventive biocide to be used with chemistries for which prior art biocides are inapplicable. | 06-28-2012 |
| 20120172437 | CONTINUOUS ON-LINE ADJUSTABLE DISINFECTANT/SANITIZER/BLEACH GENERATOR - Methods and systems for on-site, continuous generation of peracid chemistry, namely peroxycarboxylic acids and peroxycarboxylic acid forming compositions, are disclosed. In particular, an adjustable biocide formulator or generator system is designed for on-site generation of peroxycarboxylic acids and peroxycarboxylic acid forming compositions from sugar esters. Methods of using the in situ generated peroxycarboxylic acids and peroxycarboxylic acid forming compositions are also disclosed. | 07-05-2012 |
| 20120172438 | GLYCYRRHETINIC ACID ESTER DERIVATIVE SYNTHESIS METHOD AND DEOXOGLYCYRRHETINIC ACID ESTER COMPOUND - A compound represented by formula II, a preparation method, and uses thereof in treating liver damage and inflammation and so on are disclosed. A method for preparing glycyrrhetinic acid derivatives are also disclosed. In the compound represented by formula II, R | 07-05-2012 |
| 20120178810 | Extended release formulation of an antiepileptic agent - The present invention relates to an extended release formulation of an antiepileptic agent. More particularly, the present invention relates to an extended release formulation of divalproex sodium. The present invention also relates to a process for the preparation of extended release formulation of divalproex sodium. | 07-12-2012 |
| 20120178811 | METHOD OF USING BETA-HYDROXY-BETA-METHYLBUTYRATE TO REDUCE THE RISK OF INFECTION IN AN ELDERLY INDIVIDUAL - Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of β-hydroxy-β-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines. | 07-12-2012 |
| 20120202879 | MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient. | 08-09-2012 |
| 20120202880 | MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient. | 08-09-2012 |
| 20120220657 | SYNERGISTIC ANTI-INFLAMMATORY AND ANTIOXIDANT DIETARY SUPPLEMENT COMPOSITIONS - Disclosed herein are novel dietary supplement compositions comprising enriched 3-O-acetyl-11-keto-β-boswellic acid and enriched demethylated curcuminoids, wherein the composition exhibits anti-inflammatory, antiulcerogenic and anti-oxidant activities. Also disclosed are novel compositions comprising enriched 3-O-acetyl-11-keto-β-boswellic acid, enriched demethylated curcuminoids that have a synergistic effect on specific inhibition of—COX-2 and 5-LOX activity and optionally containing glucosamine, resveratrol, garlic extract, chondroitin, methlysulphonymethane, bromelain, serratiopeptidase, quercitine, gallic acid, caffeic acid, green tea extract, aspirin and ibuprofen. | 08-30-2012 |
| 20120220658 | Method for Treating Sepsis or Septic Shock - The present invention is a method for treating sepsis or septic shock using Lipoxin A4. | 08-30-2012 |
| 20120245228 | Methods and compositions for the generation of peracetic acid on site at the point-of-use - Methods and compositions for the generation of a peroxyacetic acid sanitizer in proximity to the point-of-use are disclosed. These methods comprise introducing a hydrogen peroxide-acetyl precursor solution to water, mixing, and then adding an aqueous source of a alkali metal or earth alkali metal hydroxide. Triacetin is a preferred acetyl precursor and is converted rapidly and with a high conversion rate into peracetic acid. These methods produce solutions with a high level of peracetic acid. Methods for preparing the hydrogen peroxide-acetyl precursor solution are also provided. Also disclosed are solid compositions comprising a liquid acetyl precursor, a water-soluble source of hydrogen peroxide, and a water-soluble source of alkalinity. The solid composition is a freely-flowable solid that is used as a bleaching agent and a stain remover for the treatment of articles such as fabrics, dentures, textile garments, and equipment used in the food and beverage industry. | 09-27-2012 |
| 20120252893 | ANTIMICROBIAL FORMULATION - An anti-microbial composition for treating animal feed, comprising:
| 10-04-2012 |
| 20120259013 | LIQUID DOSAGE FORMS OF ISOTRETINOIN - The present invention relates to a pharmaceutical solution comprising isotretinoin or salts thereof. The present invention further relates to the processes for preparing such compositions. | 10-11-2012 |
| 20120259014 | TOPICAL RETNOID SOLUTIONS - The present invention relates to a topical solution comprising a retinoid or its pharmaceutically acceptable salts thereof and a process of preparing it. | 10-11-2012 |
| 20120283327 | PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS OF A HYDROCORTISONE DERIVATIVE DESIGNATED AS DEINA - The hydrocortisone derivative of formula (I), whose IUPAC name is 3-[3,5-Dihydroxy-3-(2-hydroxy-acetyl)-3a,6-dimethyl-7-oxo-dodecahydro-cyclo-penta[alpha]naphthalen-6-yl]-propionic acid, designated as Deina®, is used in the treatment of atrophic tissues, particularly skin, cartilage, connective, and mucosal tissues and scalp skin. | 11-08-2012 |
| 20120289598 | COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF - The invention encompasses compositions and methods for treating or preventing a degenerative joint condition, wherein the compositions and methods include feeding the companion animal an edible composition including at least one pyruvate or salt thereof. The invention also encompasses methods for enhancing the palatability of an edible food composition including adding a palatability enhancing amount at least one pyruvate or salt thereof to the composition. | 11-15-2012 |
| 20120309828 | COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF - The invention encompasses compositions and methods for treating or preventing kidney disease in a companion animal, wherein the compositions and methods include feeding the companion animal an edible composition including at least one pyruvate or salt thereof. | 12-06-2012 |
| 20120309829 | COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF - The invention encompasses compositions and methods for maintaining or promoting a healthy body composition in a companion animal, which comprises feeding the animal an edible composition comprising one or more pyruvate in an amount effective to maintain or promote the healthy body composition, wherein maintaining or promoting the healthy body composition comprises controlling the animal's weight, for example, loss of weight or body fat, or increased percentage of lean muscle mass. | 12-06-2012 |
| 20120322872 | SUGAR ESTER PERACID ON SITE GENERATOR AND FORMULATOR - Methods and systems for on-site generation of peracid chemistry, namely peroxycarboxylic acids and peroxycarboxylic acid forming compositions, are disclosed. In particular, an adjustable biocide formulator or generator system is designed for on-site generation of peroxycarboxylic acids and peroxycarboxylic acid forming compositions from sugar esters. Methods of using the in situ generated peroxycarboxylic acids and peroxycarboxylic acid forming compositions are also disclosed. | 12-20-2012 |
| 20120322873 | USE OF A BUFFER WITH A BIOCIDE PRECURSOR - Disclosed herein are biocidal compounds and compositions, methods of using said compounds and compositions, and systems and processes for their preparation. Particularly disclosed herein are in situ generated biocides stabilized with a buffer. The biocide may include in situ generated peracetic acid produced from a peroxygen source, an acyl group donor, and a buffer. | 12-20-2012 |
| 20130005811 | ANTIMICROBIAL TREATMENT FOR SEEDS AND SPROUTS - The present disclosure encompasses embodiments of a method of reducing the microbial load of a vegetable seed or a sprout thereof, comprising contacting the vegetable seed or the sprout thereof, with a composition comprising levulinic acid and a detergent for a period suitable for reducing a bacterial population of the vegetable seed or the sprout thereof. In embodiments of the methods of the disclosure, the composition can reduce a bacterial population located on the exterior surface of the seed coat (testa) of a vegetable seed, located in or on the seed contents beneath the testa, or located on and beneath the testa of the vegetable seed. | 01-03-2013 |
| 20130018099 | DEODORIZATION OF PERACIDS - The present invention relates to compositions of peracids, such as peroxycarboxylic acids, having reduced odor compared to conventional peracid compositions. The invention further relates to methods employing such compositions, and methods of making these compositions. Typically, the reduced-odor antimicrobial compositions include an alcohol for the esterification reaction to remove short- to mid-chain length malodorous carboxylic acids. | 01-17-2013 |
| 20130046018 | DIETARY SUPPLEMENTS CONTAINING TERPENOID ACIDS OF MASLINIC ACID OR OLEANOLIC ACID AND PROCESS FOR ENHANCING MUSCLE MASS IN MAMMALS - A process for increasing lean body mass in a mammalian subject is provided that includes administering to the subject a purified quantity of maslinic acid, oleanolic acid, or a combination thereof. The administration can be orally and benefits from ingestion of an amino acid source such as dietary protein, oligopeptides, or amino acids. Administration within 2 hours of muscle-degrading exercise or on a daily basis for a period of time increases lean body mass. | 02-21-2013 |
| 20130046019 | Methods of Treatment Using 3-Bromopyruvate and Other Selective Inhibitors of ATP Production - The present invention provides methods for preventing or treating infections, especially bacterial infections, by administering selective inhibitors of ATP production to inhibit glycolytic enzymes, such as glyceraldehyde 3-phosphate dehydrogenase (GAPDH). As such, the present invention further provides methods for preventing or treating inflammation and sepsis associated with infections, as well as increased wound healing and decreased wound scarring. | 02-21-2013 |
| 20130065958 | METHODS FOR DISINFECTING OR STERILIZING ARTICLES - Disclosed herein are materials and methods for reducing, preventing, or eliminating the biological contamination of surfaces in spaces that are reasonably partitioned, defined or contained. A reagent that includes peroxides or molecules that includes peroxide bonds are contacted with at least one surface of an article. Some of these methods include disinfection within an apparatus and may include the step of volatilizing the peroxide bond containing agent, through, for example, vapour pressure and vaporization or evaporation effects, the addition of volatilization aids, or passive or assisted diffusion at modest temperatures and relatively long exposure times measured in some embodiments on the order of hours, days, or months. In some embodiments a liquid that includes a peroxide moiety is added (for example, during manufacture or subsequently) to a package, container, or any other reasonably partitioned or contained volume and allowed to migrate within the confined space for a period of time sufficient to disinfect the inner surfaces of the container and articles it contains. | 03-14-2013 |
| 20130065959 | SANITIZING MEAT WITH PERACID AND 2-HYDROXY ORGANIC ACID COMPOSITIONS - Methods and compositions for treating items to control microorganisms are provided. The method treats produce by contacting the surface of an item with an aqueous solution comprising i) an organic peracid of the formula RC(O)OOH wherein R is methyl, ethyl, n-propyl, or s-propyl; ii) a 2-hydroxy organic acid selected from tartaric acid, citric acid, malic acid, mandelic acid, and lactic acid; and iii) water wherein the aqueous solution has a pH from 2.5 to 6.0. | 03-14-2013 |
| 20130072563 | PERACID AND 2-HYDROXY ORGANIC ACID COMPOSITIONS AND METHODS FOR SANITATION AND DISEASE PREVENTION - Methods and compositions for treating living surfaces to control microorganisms are provided. The method treats produce by contacting a living surface with an aqueous solution comprising i) an organic peracid of the formula RC(O)OOH wherein R is methyl, ethyl, n-propyl, or s-propyl; ii) a 2-hydroxy organic acid selected from tartaric acid, citric acid, malic acid, mandelic acid, and lactic acid; and iii) water. | 03-21-2013 |
| 20130079408 | PERACID AND 2-HYDROXY ORGANIC ACID COMPOSITIONS AND METHODS FOR TREATING ITEMS - Methods and compositions for treating items to control microorganisms are provided. The method treats produce by contacting the surface of the item with an aqueous composition comprising i) an organic peracid of the formula RC(O)OOH wherein R is methyl, ethyl, n-propyl, or s-propyl; ii) a 2-hydroxy organic acid selected from tartaric acid, citric acid, malic acid, mandelic acid, and lactic acid; and iii) water; wherein the aqueous composition has a pH from 2.5 to 6.0. | 03-28-2013 |
| 20130090382 | METHODS, ASSAYS, AND KITS RELATED TO DICHLOROACETATE (DCA) - Embodiments of the present disclosure provide for methods, assays, and kits for predicting dosing for subjects. In addition, embodiments of the present disclosure include methods, assays, and kits, of determining if a patient can effectively metabolize one or both of phenylalanine and tryrosine. | 04-11-2013 |
| 20130096196 | PHARMACEUTICAL SEMI-SOLID COMPOSITION OF ISOTRETINOIN - An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle | 04-18-2013 |
| 20130102664 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 04-25-2013 |
| 20130102665 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 04-25-2013 |
| 20130102666 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 04-25-2013 |
| 20130102667 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 04-25-2013 |
| 20130102668 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 04-25-2013 |
| 20130102669 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 04-25-2013 |
| 20130102670 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 04-25-2013 |
| 20130102671 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 04-25-2013 |
| 20130102672 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 04-25-2013 |
| 20130143965 | MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient. | 06-06-2013 |
| 20130150444 | MODIFIED RELEASE COMPOSITIONS OF MAGNESIUM VALPROATE - The present invention relates to a modified release pharmaceutical composition comprising therapeutically effective amounts of magnesium valproate and/or its pharmaceutically acceptable solvates or mixtures thereof and at least one rate controlling polymer. Rate controlling polymer is either hydrophilic or hydrophobic in nature. Mixture of the rate controlling material or more is also used to provide formulations of the present invention. | 06-13-2013 |
| 20130158115 | Perhydrolase Variant Providing Improved Specific Activity In the Presence of Surfactant - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a variant of the | 06-20-2013 |
| 20130158116 | Perhydrolase Variant Providing Improved Specific Activity In the Presence of Surfactant - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a variant of the | 06-20-2013 |
| 20130158117 | Perhydrolase Variant Providing Improved Specific Activity In the Presence of Surfactant - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a variant of the | 06-20-2013 |
| 20130158118 | Perhydrolase Variant Providing Improved Specific Activity In the Presence of Surfactant - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a variant of the | 06-20-2013 |
| 20130172415 | TRICLOSAN-FREE ANTIBACTERIAL SOAP - Disclosed herein is an antibacterial cleansing composition. The cleansing composition is free of triclosan and comprises lactic acid/lactate and ethyl alcohol. Lactic acid/lactate is present in the composition in an amount of about 5 weight percent (wt %) to about 15 wt %, based on the total weight of the composition. Ethyl alcohol is present in an amount of about 1 wt % to about 20 wt %, based on the total weight of the composition. The pH of the composition is about 4 to about 5. The triclosan-free cleansing composition according to the invention has broad spectrum antibacterial activity that equals or even surpasses comparable formulations containing triclosan. | 07-04-2013 |
| 20130172416 | COMPOSITIONS COMPRISING ACIDIC EXTRACTS OF MASTIC GUM - The invention relates to compositions and formulations comprising isolated acidic fraction of mastic gum and uses thereof for treating impaired neurological functions as well as wound and tissue repair. | 07-04-2013 |
| 20130203849 | COMPOSITIONS AND METHODS OF TREATING EDIBLE MATTER AND SUBSTRATES THEREFOR - There are provided methods of treating edible matter comprising applying a composition comprising performic acid to the edible matter or a substrate therefor. Other embodiments are also disclosed. | 08-08-2013 |
| 20130237601 | COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF FIRE BLIGHT - The invention relates to an agent for treating and/or preventing fire blight, particularly present in wood and fruit trees, comprising formic acid and/or a salt of formic acid, particularly calcium formiate as an active component. Further disclosed is the use of formic acid and/or a salt of formic acid, particularly calcium formiate as an active component in herbicides, particularly for treating and/or preventing fire blight, and the use of formic acid and/or a salt of formic acid, particularly calcium formiate, for the production of an agent for treating and/or preventing fire blight. | 09-12-2013 |
| 20130237602 | VALPROIC ACID DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF - Biocompatible, bioerodible, sustained release drug delivery system formulated as implants, microspheres and high viscosity hyaluronic acid solutions comprise valproic acid as therapeutic agent and a biodegradable polymer, the system being effective, when placed intraocular (such as into the subtenon space or into the vitreous) to treat a retinal disease or condition. | 09-12-2013 |
| 20130261181 | Molecules to Perfect HbA1c Levels - This invention is of particular use to patients with Diabetes Mellitus. It uses alkyl analogs of the methyl pyruvate (MP) family to provide energy and improve insulin and glucose homeostasis via accelerated intracellular delivery of protons, pyruvate and ATP from each MP. The energy upregulates cellular cross talk and networking resulting in a surge of ATP enabling NADH (via glycolysis) that enables pancreatic islet cells to obtain increased ATP allowing increased insulin manufacture. This process improves cellular respiration, expedites protein, lipid and hormone manufacture. The increased energy also enables telomeres and delays Hayflick limit. Instead of cellular repair, silence, or apoptosis, energy is allocated for cell/organ function. This invention curbs inflammation and ROS by idealizing cellular respiration and diminishing hyperglycemia. In turn a reduction of advanced glycation end products (AGEs), lessened target RNA and nucleic acid toxins, i.e., diminished HbA1c occurs. By decreased drain of cellular energy, genomic function improves. | 10-03-2013 |
| 20130261182 | ENZYMES USEFUL FOR PERACID PRODUCTION - Acetyl xylan esterases and variants thereof having perhydrolytic activity are provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. Multi-component peracid generation systems comprising an enzyme catalyst having perhydrolytic activity are also provided, as are methods of using the present enzyme catalyst to produce peroxycarboxylic acids. The polypeptide having perhydrolytic activity may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, paper pulp processing, and personal care applications. | 10-03-2013 |
| 20130267595 | MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient. | 10-10-2013 |
| 20130267596 | Methods of Reducing Hair Loss and/or Facilitating Hair Growth and/or Regrowth - The present disclosure relates to methods of retarding hair loss or facilitating hair growth and/or regrowth. More specifically, the present disclosure relates to methods of using the disclosed compositions to increase the rate of terminal hair growth and/or regrowth in a mammal. | 10-10-2013 |
| 20130274334 | SULFOPEROXYCARBOXYLIC ACIDS, THEIR PREPARATION AND METHODS OF USE AS BLEACHING AND ANTIMICROBIAL AGENTS - The present invention relates to novel sulfoperoxycarboxylic acid compounds, and methods for making and using them. The sulfoperoxycarboxylic compounds of the invention are storage stable, water soluble and have low to no odor. Further, the compounds of the present invention can be formed from non-petroleum based renewable materials. The compounds of the present invention can be used as antimicrobials, and bleaching agents. The compounds of the present invention are also suitable for use as coupling agents. | 10-17-2013 |
| 20130289113 | ENZYMES USEFUL FOR PERACID PRODUCTION - Acetyl xylan esterases and variants thereof having perhydrolytic activity are provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. Multi-component peracid generation systems comprising an enzyme catalyst having perhydrolytic activity are also provided, as are methods of using the present enzyme catalyst to produce peroxycarboxylic acids. The polypeptide having perhydrolytic activity may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, paper pulp processing, and personal care applications. | 10-31-2013 |
| 20130289114 | ENZYMES USEFUL FOR PERACID PRODUCTION - Acetyl xylan esterases and variants thereof having perhydrolytic activity are provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. Multi-component peracid generation systems comprising an enzyme catalyst having perhydrolytic activity are also provided, as are methods of using the present enzyme catalyst to produce peroxycarboxylic acids. The polypeptide having perhydrolytic activity may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, paper pulp processing, and personal care applications. | 10-31-2013 |
| 20130289115 | ENZYMES USEFUL FOR PERACID PRODUCTION - Acetyl xylan esterases and variants thereof having perhydrolytic activity are provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. Multi-component peracid generation systems comprising an enzyme catalyst having perhydrolytic activity are also provided, as are methods of using the present enzyme catalyst to produce peroxycarboxylic acids. The polypeptide having perhydrolytic activity may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, paper pulp processing, and personal care applications. | 10-31-2013 |
| 20130289116 | EPILEPSY TREATMENT EMPLOYING KETOGENIC COMPOUNDS WHICH ARREST APOPTOSIS (AS AMENDED) - A method is provided for treating a patient suffering from apoptosis of tissue comprising administering to that subject a therapeutically effective amount of one or more ketogenic compounds such that a physiological ketosis is produced sufficient to arrest said apoptosis. Preferably the apoptosis is of cerebral tissue such as that associated with acute intractible seizures, particularly with status epilepticus. | 10-31-2013 |
| 20130338228 | METHODS FOR FACILITATING MUSCLE RECOVERY AFTER A PERIOD OF DISUSE USING BETA-HYDROXY-BETA-METHYLBUTYRATE - Disclosed are methods utilizing beta-hydroxy-beta-methylbutyrate (HMB) for facilitating the recovery of muscle after a period of muscle disuse. The HMB facilitates the recovery of muscle mass in an individual and can also be used to prevent further muscle atrophy typically associated with muscle reloading after extended periods of muscle disuse in the individual. The methods disclosed may be particularly suitable for older adults. | 12-19-2013 |
| 20140011874 | TREATMENT OF VIRAL INFECTIONS - The invention provides low concentration, stable compositions for the treatment of lesions associated with herpes viral infections. The compositions are in a form selected from creams and gels containing trichloroacetic acid in an amount of between 2.5% (m/m) and 6% (w/w) of the weight of the cream or gel. Preferably the cream contains about 5% and the gel about 2.5% of the trichloroacetic acid. | 01-09-2014 |
| 20140011875 | METHODS AND COMPOSITIONS FOR THE GENERATION OF PERACETIC ACID ON SITE AT THE POINT-OF-USE - Methods and compositions for the generation of a peroxyacetic acid sanitizer in proximity to the point-of-use are disclosed. These methods comprise introducing a hydrogen peroxide-acetyl precursor solution to water, mixing, and then adding an aqueous source of a alkali metal or earth alkali metal hydroxide. Triacetin is a preferred acetyl precursor and is converted rapidly and with a high conversion rate into peracetic acid. These methods produce solutions with a high level of peracetic acid. Methods for preparing the hydrogen peroxide-acetyl precursor solution are also provided. Also disclosed are solid compositions comprising a liquid acetyl precursor, a water-soluble source of hydrogen peroxide, and a water-soluble source of alkalinity. The solid composition is a freely-flowable solid that is used as a bleaching agent and a stain remover for the treatment of articles such as fabrics, dentures, textile garments, and equipment used in the food and beverage industry. | 01-09-2014 |
| 20140039050 | METHOD FOR PREVENTING BACTERIAL INFECTION IN A FERMENTATION PROCESS - The present invention relates to an improved process for fermenting a sugar-containing material and an improved method for preventing bacterial infection in a fermentation process by using performic acid. The fermentation process is primarily the fermentation of sugar-containing material, for instance sugarcane, into ethanol. The present invention further relates to the manufacture of ethanol and the ethanol so obtained. | 02-06-2014 |
| 20140039051 | Cleaning and disinfection agent for medical instruments - The invention relates to a cleaner and/or disinfectant for medical and/or surgical elements and apparatuses which is formulated as a powder. It comprises at least one peroxide, at least one acylating agent for releasing peracetic acid from the peroxide in aqueous solution, and also at least one nonionic surfactant. According to the invention, it is provided that it comprises agents for adjusting a pH of a 2% strength aqueous solution to pH 7.5 to 9 and is formulated as granules, where peroxide and/or acylating agent are coated with nonionic surfactant. | 02-06-2014 |
| 20140080908 | COMPOSITIONS AND METHODS FOR IMPROVING OR PREVENTING DEPRESSION-LIKE SYMPTOMS - The invention provides methods of improving and/or preventing one or more depression-like symptoms by administering to an individual an effective amount of calcium L-threonate. Also provided are related kits and articles of manufacture. | 03-20-2014 |
| 20140094518 | METHOD FOR REGULATING RETINAL ENDOTHELIAL CELL VIABILITY - Here provided is a method for regulating retinal endothelial cell viability in a mammal by administering to the mammal a therapeutically effective amount of a quinic acid analog. The method may be applied to prevent, treat or cure pathological conditions of retinal endothelial cells associated with radiation retinopathy, diabetic retinopathy and chemotherapy for retinoblastoma. | 04-03-2014 |
| 20140100277 | SOLUTIONS AND METHODS OF MAKING SOLUTIONS TO KILL OR DEACTIVATE SPORES, MICROORGANISMS, BACTERIA AND FUNGUS - Exemplary embodiments of solutions of plasma activated water and peroxyacetic acid are disclosed herein. In addition, exemplary embodiments of methods for making solutions are disclosed herein. Some methods include exposing water to a plasma gas to activate the water, adding acetic acid to the activated water; and mixing the acetic acid and activated water to form a solution. Additional exemplary methods include adding acetic acid to water to form a solution, mixing solution of acetic acid and water together; and exposing the solution to a plasma gas to activate the solution. Another exemplary embodiment includes exposing water to a plasma gas to activate the water; adding an acetyl group donor to the activated water; and mixing the acetyl group donor and activated water to form a solution. | 04-10-2014 |
| 20140100278 | Injectable Formulation for Treatment and Protection of Patients Having an Inflammatory Reaction or an Ischemia-Reperfusion Event - The present invention relates to compounds according to formula (I) for medical use. The compounds are particularly suitable for the treatment and/or prevention of a medical condition involving hypoxic, anoxic and/or inflamed mammalian tissue. Furthermore, the invention relates to the use of said compounds for preparing a medicament and to pharmaceutical preparations comprising such compounds. The invention also relates to methods of treating or protecting patients having or being prone to develop a medical condition involving hypoxic, anoxic and/or inflamed mammalian tissue, the methods comprising administration of a therapeutically effective amount of such compounds. | 04-10-2014 |
| 20140113966 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a | 04-24-2014 |
| 20140113967 | Stable Peracid-Containing Compositions - Methods have been developed for incorporation of peracid compounds and related compositions into a non-aqueous medium. The peracid incorporated into the non-aqueous medium is stable and keeps its chemical and antimicrobial activity for extended durations. The non-aqueous medium may be removed just prior to or during application of the peracid. | 04-24-2014 |
| 20140121271 | NON-ENZYMATIC REMOVAL OF HYDROGEN PEROXIDE FROM PERACIDS - Peroxycarboxylic acid compositions having reduced hydrogen peroxide content are generated according to the invention, having enhanced antimicrobial efficacy. Simultaneously, a stable hydrogen peroxide and active oxygen coordinating compound complex is generated and has utility as a recycled bleaching component. In particular, methods of using an active oxygen coordinating compound to selectively and non-destructively remove hydrogen peroxide are provided. Preferred active oxygen coordinating compounds suitable for use with the peroxycarboxylic acid compositions include nitrogen-containing compounds, preferably urea, urea copolymers and/or derivatives, PVP, PVP copolymers and/or derivatives, and/or inorganic carbonates. | 05-01-2014 |
| 20140121272 | DEODORIZATION OF PEROXYCARBOXYLIC ACIDS USING CHAOTROPIC AGENTS - Treated peroxycarboxylic acid compositions and methods of using the same are provided to eliminate or reduce malodors associated therewith. Peroxycarboxylic acid compositions are treated with odor reducing agents, including various chaototropic agents. The invention further relates to methods employing the reduced odor peroxycarboxylic acid compositions. | 05-01-2014 |
| 20140121273 | METHOD FOR TREATMENT OF MAGNESIUM AND POTASSIUM DEFICIENCIES - A method for the treatment of depleted intracellular and serum magnesium levels by administration of a highly bioavailable magnesium salt is disclosed. A prescription dispensing system is also disclosed. The highly bioavailable magnesium salt can be administered alone or as adjunctive therapy in conjunction with various medications that cause or exacerbate depleted intracellular magnesium levels, such as renal magnesium wasting medications, including diuretics, immunosuppressants, chemotherapeutic agents, and antibiotics. The highly bioavailable magnesium salt can also be used as adjunctive therapy in conjunction with Class III anti-arrhythmic drugs to attenuate the QTc interval and reduce the risk of fatal arrhythmias, which are a common risk associated with Class III anti-arrhythmic drugs. The administration of a highly bioavailable magnesium salt also serves to restore intracellular potassium levels to normal ranges in patients who remain hypokalemic despite potassium therapy. | 05-01-2014 |
| 20140121274 | ACIDIC SOLID ORAL COMPOSITIONS WITHOUT EROSIVE POTENTIAL IN SALIVA AND METHOD FOR DETERMINING EROSIVE POTENTIAL IN SALIVA - Acidic oral compositions having calcium contents and effective pH-values in the area indicated by grey-tone in FIG. | 05-01-2014 |
| 20140128467 | METHODS OF TREATMENT USING A BCAT1 INHIBITOR - The present invention is directed to methods of using inhibitors of the cytosolic form of BCAT in the treatment of cancer, rheumatoid arthritis, and bone disease. | 05-08-2014 |
| 20140128468 | TOPICAL FILM-FORMING COMPOSITION, AND USE THEREOF FOR TREATING MYCOSES - The present invention relates to a topical film-forming composition for the treating dermatophytosis, specifically mycoses of the feet and, in particular, for treating the symptoms associated with dermatophytosis, specifically the symptoms associated with athlete's foot. The composition is particularly suitable for treating cracking, and for promoting the healing of skin lesions caused by said inflammation. The present composition is also suitable for preventing bacterial or fungal proliferation in the damaged skin. | 05-08-2014 |
| 20140135394 | METHOD OF PREPARATION AND COMPOSITION OF ANTIMICROBIAL ICE - Composition and method for production of peroxycarboxylic acid solutions for various disinfection and cleaning compositions that utilizes non-equilibrium peroxycarboxylic acid. More specifically compositions comprise peracetic acid (PAA) and methods for making non-equilibrium PAA are provided. Frozen compositions useful as antimicrobial ice are provided. | 05-15-2014 |
| 20140142180 | METHODS OF TREATING TUMORS HAVING ELEVATED MCT1 EXPRESSION - In some aspects, compositions and methods useful for classifying tumor cells, tumor cell lines, or tumors according to predicted sensitivity to 3-bromopyruvate (3-BrPA) are provided. In some aspects, methods of identifying subjects with cancer who are candidates for treatment with 3-BrPA are provided. In some aspects, compositions useful for subjects with cancers that express increased levels of MCT1 are provided. In some aspects, methods of treating subjects with cancers that express increased levels of MCT1 are provided. In some aspects, methods of identifying anti-tumor agents the efficacy of which is at least in part dependent on transporter-mediated uptake are provided. | 05-22-2014 |
| 20140171505 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF DISORDERS - Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus. | 06-19-2014 |
| 20140171506 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF DISORDERS - Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus. | 06-19-2014 |
| 20140179780 | PHARMACEUTICAL COMPOSITION CONTAINING OLEANOLIC ACID ACETATE AS AN ACTIVE INGREDIENT FOR PREVENTING OR TREATING TLR- OR IL-6-MEDIATED DISEASES - The present invention relates to a pharmaceutical composition including oleanolic acid acetate or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating TLR- and IL-6-mediated diseases, and a pharmaceutical composition including an adzuki bean extract containing the compound or the salt thereof, or a fraction thereof as an active ingredient for preventing or treating TLR- and IL-6-mediated diseases. The adzuki bean extract or the compound of the present invention is derived from a natural resource that has been used as a natural medicine for a long time, and it is widely used for the development of prophylactic or therapeutic agents for TLR- and IL-6-mediated diseases, for example, atopic dermatitis or arthritis. | 06-26-2014 |
| 20140249222 | METHOD OF ADMINISTRATION OF GAMMA HYDROXYBUTYRATE WITH MONOCARBOXYLATE TRANSPORTERS - One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition. | 09-04-2014 |
| 20140249223 | METHODS FOR IMPROVING BRAIN DEVELOPMENT AND COGNITIVE FUNCTION USING BETA-HYDROXY-BETA METHYLBUTYRATE - Disclosed are methods for enhancing neural function in an individual, such as an older adult. The methods include administering nutritional compositions comprising HMB to the individual. The nutritional compositions provide benefits for individuals that have or may be at risk of having cognitive decline, cognitive impairment, and neural dysfunction, typically resulting from cognitive diseases associated with neurodegenerative diseases. | 09-04-2014 |
| 20140256810 | LOW MELTING PROPIONIC ACID DERIVATIVE PARTICLES FOR USE IN ORAL DOSAGE FORMS - Low melting propionic acid derivative particles that are free flowing and have significantly reduced or eliminated throat burn are disclosed. A method of manufacturing the low melting propionic acid derivative particles; dosage forms containing the low melting propionic acid derivative particles; methods of manufacturing the dosage forms; and methods of treatment using the dosage forms are also disclosed. | 09-11-2014 |
| 20140275254 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FUNGAL INFECTIONS - There is provided pharmaceutical compositions suitable for topical application to the nail for the treatment of nail diseases such as onychomycosis, comprising a urea-based component, a diol component, such as propylene glycol, an organic acid component, such as lactic acid, and a triol component, such a glycerol. There is further provided methods of improving the storage stability of a pharmaceutical composition suitable for topical application to the skin and/or nails comprising such urea-based components, diol components, organic acid components, and, optionally, an aqueous base, which method comprises adding a triol component, such a glycerol, to that composition prior to said storage. | 09-18-2014 |
| 20140316002 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT - The present disclosure relates to lipid compounds of general formula (I) wherein R | 10-23-2014 |
| 20140343144 | METHOD, PHARMACEUTICAL COMPOSITION AND KIT FOR APPLYING METFORMIN AND SODIUM BUTYRATE IN KRAS MUTATION CANCER TREATMENT - A method for using metformin and sodium butyrate in combination to treat a cancer patient with K-ras mutation is disclosed. When administering the pharmaceutical composition to a cancer patient, Metformin and sodium butyrate offer cooperatively therapeutic efficacy. The present invention also discloses a pharmaceutical composition and a pharmaceutical kit containing both aforementioned. The application of the method, the pharmaceutical composition and the pharmaceutical kit of the present invention are advantageous for improving the treatment effect to cancer patients with K-ras mutation. | 11-20-2014 |
| 20140364501 | COMPOSITIONS OF ABSCISIC ACID FOR ANIMAL HEALTH - The invention relates to compositions comprising abscisic acid, and/or salts, derivatives and analogs thereof, and methods of using the same for improving the health and survival of animal offspring. | 12-11-2014 |
| 20150011632 | IN SITU GENERATION OF PEROXYCARBOXYLIC ACIDS AT ALKALINE pH, AND METHODS OF USE THEREOF - The present disclosure is related to percarboxylic acid compositions formed in situ in non-equilibrium reactions. The peroxycarboxylic acid compositions are formed using ester based starting materials. Methods for using the percarboxylic acid compositions are also disclosed. | 01-08-2015 |
| 20150025143 | BETA-HYDROXY-BETA-METHYLBUTYRIC ACID FOR IMPROVING GLUCOSE TOLERANCE - The use beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance in a pediatric individual or in an adult individual is disclosed. In certain embodiments, the beta-hydroxy-beta-methylbutyric acid is administered via a nutritional composition. | 01-22-2015 |
| 20150025144 | METHOD OF PACKAGING FOOD - The invention proposes a container further extending the shelf life of foods, particularly berries, by including an active agent having antifungal capability into the container surface so that when the fruit is packaged inside the container it is permanently exerted an antifungal effect over the surface, which is the place on the longer determinants occurs, but also contributing to preserve the general environment. Also it proposes a preparation process and its use. | 01-22-2015 |
| 20150031762 | Antimicrobial Formulations with Pelargonic Acid - An antimicrobial composition for extending the shelf-life of water, feed or feed ingredients, comprising: water, a mixture of CrC18 organic acids, a mixture of CrC24 aldehydes, 5-25 wt. % pelargonic acid, and 5-30 wt. % trans-2-hexenal. | 01-29-2015 |
| 20150031763 | DEODORIZATION OF PERACIDS - The present invention relates to compositions of peracids, such as peroxycarboxylic acids, having reduced odor compared to conventional peracid compositions. The invention further relates to methods employing such compositions, and methods of making these compositions. Typically, the reduced-odor antimicrobial compositions include an alcohol for the esterification reaction to remove short- to mid-chain length malodorous carboxylic acids. | 01-29-2015 |
| 20150031764 | SUGAR ESTER PERACID ON SITE GENERATOR AND FORMULATOR - Methods and systems for on-site generation of peracid chemistry, namely peroxycarboxylic acids and peroxycarboxylic acid forming compositions, are disclosed. In particular, an adjustable biocide formulator or generator system is designed for on-site generation of peroxycarboxylic acids and peroxycarboxylic acid forming compositions from sugar esters. Methods of using the in situ generated peroxycarboxylic acids and peroxycarboxylic acid forming compositions are also disclosed. | 01-29-2015 |
| 20150031765 | TREATMENT OF COGNITIVE IMPAIRMENT - The present invention relates to a compound with the core structure of formula (I), or pharmaceutically acceptable salts or esters, solvates, or prodrugs thereof, for use in the treatment of cognitive impairment in a mammal. The compound is preferably isosteviol or steviol, or pharmaceutically acceptable salts or esters, solvates, or prodrugs thereof. | 01-29-2015 |
| 20150057349 | 4-OXO-2-PENTENOIC ACID AND THE HEALTH OF THE DIGESTIVE TRACT - The present invention relates generally to compositions with a health benefit. In particular, the invention relates to the field of inflammatory disorders of the digestive tract, for example, ileitis, colitis, rectal inflammation, pharyngitis, leaky gut syndrome, irritable bowel syndrome and inflammatory bowel disease. A subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of inflammatory disorders of the digestive tract. | 02-26-2015 |
| 20150057350 | FIBROSIS BIOMARKERS AND METHODS OF USING SAME - Methods and systems for using fibrosis biomarkers associated with a prolonged period of physical inactivity are provided. Also provided is a method of reducing the effect of prolonged physical inactivity on the development of fibrosis in a subject who is experiencing or is expected to experience prolonged physical inactivity in the near future by administering a therapeutically effective amount of a leucine metabolite (e.g., β-hydroxy-β-methylbutyric acid (HMB)) to the subject. | 02-26-2015 |
| 20150073052 | MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient. | 03-12-2015 |
| 20150080467 | VAGINAL SUPPOSITORY COMPRISING LACTIC ACID - The present invention relates to a vaginal suppository comprising an inert vehicle and lactic acid or a salt thereof for the treatment and/or prophylaxis of disorders in the urogenital tract. | 03-19-2015 |
| 20150087706 | 4-OXO-2-PENTENOIC ACID AND LIVER DISORDERS - The present invention relates generally to compositions with a health benefit. In particular, the invention relates to treatment or prevention of liver disorders. A subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of liver disorders. A further subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of liver disorders linked to an insufficient activity of phase II enzymes in the liver. | 03-26-2015 |
| 20150087707 | 4-OXO-2-PENTENOIC ACID AND CARDIOVASCULAR HEALTH - The present invention relates generally to compositions with a health benefit. In particular, the invention relates to the field of cardiovascular disorders, for example, atherosclerosis, high blood pressure, coronary heart disease, myocardial infarction, angina pectoris, stroke, and heart failure. A subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of cardiovascular disorders. | 03-26-2015 |
| 20150094369 | WATER TEMPERATURE AS A MEANS OF CONTROLLING KINETICS OF ONSITE GENERATED PERACIDS - Methods and systems for temperature-controlled, on-site generation of peracids, namely peroxycarboxylic acids and peroxycarboxylic acid forming compositions are disclosed. In particular, methods for using an adjustable biocide formulator or generator system overcome the limitations of temperature on the kinetics of the peracid generation and/or peracid decomposition inside an adjustable biocide formulator or generator system. The methods include the controlling of the temperature of at least one raw starting material, namely water, to improve upon methods of on-site generation of peracids. The methods allow for the generation of user-selected chemistry without regard to the ambient temperatures of the raw starting materials and/or the biocide formulator or generator system. | 04-02-2015 |
| 20150105463 | Sodium Pyruvate Oral Rehydration Salt Composition for Treating Hypovolemia or Hyponatration Associated with Hypohydration - Disclosed in the present invention is a sodium pyruvate oral rehydration salt composition for treating hypovolemia or hyponatration associated with hypohydration, said composition containing the following components: (i) 2.0-6.0 parts by weight of sodium pyruvate; (ii) 1.5-17.0 parts by weight of sodium chloride; (iii) 0-2.0 parts by weight of potassium chloride; and (iv) 10.0-50.0 parts by weight of glucose anhydrous or other carbohydrates. The weight of components (i)+(ii)+(iii)+(iv) constitutes 50-100% of the total weight of the composition. | 04-16-2015 |
| 20150105464 | 4-OXO-2-PENTENOIC ACID AND BRAIN HEALTH - The present invention relates generally to compositions with a health benefit. In particular, the invention relates to the field of brain health, for example brain protection, maintenance of cognitive function, prevention of cognitive decline and prevention of cognitive disorders. A subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of cognitive decline. | 04-16-2015 |
| 20150111967 | METHOD FOR MAKING A PEROXYCARBOXYLIC ACID - The present invention relates to apparatus and methods for making a peroxycarboxylic acid. The apparatus includes a reaction catalyst and a guard column for pretreating one or more reagents, which can increase the life, activity, and/or safety of the reaction catalyst. The peroxycarboxylic acid compositions made by the method and apparatus can include one or more peroxycarboxylic acids. | 04-23-2015 |
| 20150133552 | POLYHYDROXYLATED PENTACYCLIC TRITERPENE ACIDS AS HMG-COA REDUCTASE INHIBITORS - The present invention relates to certain polyhydroxylated pentacyclic triterpene acids of formula (I) for use as HMG-CoA reductase inhibitors in the prophylactic and/or therapeutic treatment of a disease, disorder or condition that responds to a reduction of the HMG-CoA reductase activity in a mammal, preferably a human being. The present invention further relates to certain mixtures and plant extracts comprising euscaphic acid and tormentic acid, wherein the amount of euscaphic acid to tormentic acid exceeds a certain ratio. Further, the present invention also relates to a formulation, preferably pharmaceutical or nutraceutical formulation, comprising one or more of said compounds of formula (I), a composition according to the present invention or a plant extract according to the present invention. Also, the present invention relates to a process for obtaining certain polyhydroxylated pentacyclic triterpene acids of formula (I), a composition according to the present invention or a plant extract according to the present invention. | 05-14-2015 |
| 20150141511 | DOPAMINERGIC MIMETICS - A method is described for providing acute symptomatic relief to a subject with Parkinson's Disease (PD) or other CNS disorders resulting from dopamine deficiency in the brain comprising administering to said subject an amount of a ketogenic material sufficient to produce a ketosis in the subject sufficient to provide therapeutic benefit in such neurological disorders. Preferred materials produce a ketosis is such that the total concentration of acetoacetate and (R)-3-hydroxybutyrate in the blood of the subject is raised to between 0.1 and 30 mM. | 05-21-2015 |
| 20150148416 | USE OF SAPONIFIED TALL OIL FATTY ACID - The present invention relates to use of a tall oil fatty acid which is modified by saponification in enhancing rumen fermentation and/or lowering rumen methane production. | 05-28-2015 |
| 20150148417 | SYNTHESIS AND BIOLOGICAL STUDIES OF AN ISOMERIC MIXTURE OF (E/Z) ISOXYLITONES AND ITS ANALOGUES - The invention relates to an anti-epileptic isoxylitone, 2,2′-(3,5,5-Trimethyl-2-cylohexen-1-ylidene)acetic acid. | 05-28-2015 |
| 20150306053 | THERAPEUTIC METHOD - The present invention relates generally to a method of down-regulating an inflammatory response in a mammal and to agents useful for same. More particularly, the present invention relates to a method of down-regulating an inflammatory response in the reproductive tract or external genital tissue of a female mammal by contacting the mucosal tissue of the reproductive tract and/or genitalia with lactic acid and to agents useful for same. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by an aberrant, unwanted or otherwise inappropriate inflammatory response including, for example, atrophic vaginitis, irritant vaginitis or infectious vaginitis. | 10-29-2015 |
| 20150320704 | COMPOSITIONS AND METHODS FOR TREATMENT OF HAIR LOSS - Potassium ion channel opening agents, other than ATP-sensitive potassium channel opening agents, have the ability to stimulate hair growth when topically applied to the scalp. | 11-12-2015 |
| 20150359764 | METHODS OF TREATMENT USING 3-BROMOPYRUVATE AND OTHER SELECTIVE INHIBITORS OF ATP PRODUCTION - The present invention provides methods for preventing or treating infections, especially bacterial infections, by administering selective inhibitors of ATP production to inhibit glycolytic enzymes, such as glyceraldehyde 3-phosphate dehydrogenase (GAPDH). As such, the present invention further provides methods for preventing or treating inflammation and sepsis associated with infections, as well as increased wound healing and decreased wound scarring. | 12-17-2015 |
| 20160000735 | METHODS FOR CLASSIFYING A CANCER AS SUSCEPTIBLE TO TMEPAI-DIRECTED THERAPIES AND TREATING SUCH CANCERS - The invention provides methods for classifying a cancer as susceptible to transmembrane prostate androgen induced (TMEPAI)-directed therapies, and methods for treating such cancers. The field of the invention pertains generally to medicine, pathology and oncology. More particularly, it addresses the treatment of breast cancer, such as triple-negative breast cancer, using a transmembrane prostate androgen induced (TMEPAI)-directed therapy. | 01-07-2016 |
| 20160008276 | COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES | 01-14-2016 |
| 20160015662 | METHOD OF ADMINISTRATION OF GAMMA HYDROXYBUTYRATE WITH MONOCARBOXYLATE TRANSPORTERS - One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition. | 01-21-2016 |
| 20160022617 | TREATMENT OF INSULIN RESISTANCE ASSOCIATED WITH PROLONGED PHYSICAL INACTIVITY - Insulin resistance biomarkers and related methods of using the biomarkers are provided. The biomarkers may be blood biomarkers and include C-peptide, Insulin-Like Growth Factor-Binding Protein 2 (IGFBP-2), and Leptin. Also provided is a method of reducing the effect of prolonged physical inactivity on insulin resistance in a subject who is experiencing prolonged physical inactivity, or who is expected to experience prolonged physical inactivity in the near future. | 01-28-2016 |
| 20160031809 | SUGAR ESTER PERACID ON SITE GENERATOR AND FORMULATOR - Methods and systems for on-site generation of peracid chemistry, namely peroxycarboxylic acids and peroxycarboxylic acid forming compositions, are disclosed. In particular, an adjustable biocide formulator or generator system is designed for on-site generation of peroxycarboxylic acids and peroxycarboxylic acid forming compositions from sugar esters. Methods of using the in situ generated peroxycarboxylic acids and peroxycarboxylic acid forming compositions are also disclosed. | 02-04-2016 |
| 20160038446 | METHOD FOR IMPEDING SKIN INFLAMMATORY RESPONSE TO AN ENERGY INJURY - A method for treating skin that is subject to an energy injury including the application of concentrated l-lactic acid to the injury area during the inflammatory response of the skin. Reapplication is shown to further reduce the inflammatory symptoms and improve healing time. The concentration of approximately ten percent by weight with around 2.34 pH is proven to be ideal to impede the skin's inflammatory response for sunburn and elevated temperature thermal burns and prevent associated cellular damage compared to untreated sunburns. | 02-11-2016 |
| 20160045464 | COMPOSITIONS AND METHODS FOR INHIBITING INTIMAL HYPERPLASIA - Methods are provided for preventing, inhibiting, or treating intimal hyperplasia in a patient who has undergone a coronary bypass procedure that include providing a solution comprising DCA added to water; and administering the solution orally to a patient to prevent, inhibit, or treat intimal hyperplasia. | 02-18-2016 |
| 20160058005 | SYNERGISTIC ANTIMICROBIAL FORMULATION - Home care formulation comprising a formulation of a sulfonic acid derivative and a carboxylic acid. | 03-03-2016 |
| 20160058038 | ANIMAL FEED PRESERVATIVE, SUPPLEMENT AND METHODS - Embodiments herein relate to animal feed preservatives including byproducts containing levulinic acid and methods of making and using the same. In an embodiment, a method of making an animal feed preservative is included. The method can include obtaining an acidic byproduct of a manufacturing process. The acidic byproduct can include at least about 1% by weight levulinic acid or a salt thereof. The method can further include mixing the acidic byproduct with a base to form the animal feed preservative. The animal feed preservative can include at least about 5 wt. % of the acid byproduct. In various embodiments, a method of reducing the amount of mycotoxins formed in an animal feed product during storage is included. In various embodiments, an animal feed preservative or supplement is included. Other embodiments are also included herein. | 03-03-2016 |
| 20160058720 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF DISORDERS - Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus. | 03-03-2016 |
| 20160067198 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS - Halogenated aliphatic carboxylic acids, salts and/or oligomers or polymers thereof, which exhibit a devitalizing effect of neoplastic tissues, are disclosed. Methods and uses that utilize these compounds for the treatment of medical conditions associated with a neoplastic tissue are also disclosed. Further disclosed are methods and uses that utilize these compounds for reducing or abolishing blood and lymph as well local dissemination of malignant neoplastic cells during a surgical removal thereof, thereby preventing recurrences and distance metastases, and/or inducing immune response to potentially malignant, pre-malignant and/or malignant cells. Further disclosed are novel oligomeric forms of halogenated aliphatic carboxylic acids, pharmaceutical compositions containing same and uses thereof. | 03-10-2016 |
| 20160074349 | EPILEPSY TREATMENT EMPLOYING KETOGENIC COMPOUNDS WHICH ARREST APOPTOSIS - A method is provided for treating a patient suffering from apoptosis of tissue comprising administering to that subject a therapeutically effective amount of one or more ketogenic compounds such that a physiological ketosis is produced sufficient to arrest said apoptosis. Preferably the apoptosis is of cerebral tissue such as that associated with acute intractible seizures, particularly with status epilepticus. | 03-17-2016 |
| 20160081953 | TREATMENT OF VIRAL INFECTIONS - The invention provides low concentration, stable compositions for the treatment of lesions associated with herpes viral infections. The compositions are in a form selected from creams and gels containing trichloroacetic acid in an amount of between 2.5% (m/m) and 6% (w/w) of the weight of the cream or gel. | 03-24-2016 |
| 20160088839 | METHOD OF PREPARATION AND COMPOSITION OF ANTIMICROBIAL ICE - Composition and method for production of peroxycarboxylic acid solutions for various disinfection and cleaning compositions that utilizes non-equilibrium peroxycarboxylic acid. More specifically compositions comprise peracetic acid (PAA) and methods for making non-equilibrium PAA are provided. Frozen compositions useful as antimicrobial ice are provided. | 03-31-2016 |
| 20160095339 | NUTRITIONAL COMPOSITION FOR GASTROINTESTINAL ENVIRONMENT TO PROVIDE IMPROVED MICROBIOME AND METABOLIC PROFILE - The present disclosure a method and nutritional composition for improving the microbiome and metabolic profile of a pediatric subject, which includes administering to a pediatric subject a composition having up to about 7 g/100 kCal of a protein or protein equivalent source; up to about 7 g/100 kCal of a fat or lipid source; at least about 5 g/100 kCal of a carbohydrate; at least about 0.05 mg/100 kCal of bacterial metabolites; and either a probiotic or a prebiotic composition, or both. | 04-07-2016 |
| 20160106131 | USE OF HMB TO IMPROVE QUALITY OF LIFE FOR HOSPITALIZED PATIENTS - A method of care is described that includes administering an effective amount of β-hydroxy-β-methylbutyrate (HMB) to an adult or elderly patient to improve the patient's quality of life during or after hospitalization of the patient. The improved quality of life may encompass the general health, physical health, or mental health of the patient. | 04-21-2016 |
| 20160106668 | CHOLECYSTOKININ SECRETION-PROMOTING COMPOSITION - A method is provided to promote secretion of cholecystokinin (CCK) by administering an active component. The active component includes acrylic acid and/or an unsaturated aldehyde having a main chain of 4 to 12 carbon atoms having a double bond in at least position 2 or 4, where the main chain has 4 to 9 carbon atoms when there is a double bond in only position 2, and the main chain has 9 to 12 carbon atoms when there is a double bond in only position 4. The cholecystokinin secretion-promoting composition can be used as an appetite suppressant. By adding this cholecystokinin secretion-promoting composition to food, appetite-suppressing food products can be provided. | 04-21-2016 |
| 20160128920 | Synergistic Preservative Blends - A synergistic preservative composition comprises sorbic acid or a salt thereof, benzyl alcohol, and a mixture of (i) 1,2-propanediol and/or 1,3-propanediol, and (ii), 4-butanediol and/or 1,3-butanediol. The composition is particularly suited for the preservation of cosmetics and personal care products. | 05-12-2016 |
| 20160135453 | SHELF STABLE, REDUCED CORROSION, READY TO USE PEROXYCARBOXYLIC ACID ANTIMICROBIAL COMPOSITIONS - The present invention relates to shelf stable and/or less corrosive peroxycarboxylic acid antimicrobial compositions, including ready-to-use compositions. Shelf stable compositions can include defined ratios of hydrogen peroxide to peroxycarboxylic acid and/or hydrogen peroxide to protonated carboxylic acid, but need not include strong acid. Reduced corrosion compositions can include carboxylic acid and corrosion inhibitor at acid pH. Compositions of the invention can have advantageous activity against spores. | 05-19-2016 |
| 20160143867 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANCER - The invention relates to methods and pharmaceutical compositions for treating cancer. In particular, the present invention relates to a compound selected from the group consisting of gamma-hydroxybutyrate (GHB), GHB derivatives, and GHB structurally-related compounds thereof, or a pharmaceutically acceptable salt thereof for use in the treatment of cancer in a subject in need thereof. | 05-26-2016 |
| 20160169909 | COMPOSITION CONTAINING PYRUVATE DEHYDROGENASE KINASE INHIBITOR FOR TREATING CHRONIC INFLAMMATORY PAIN | 06-16-2016 |
| 20160175267 | SYSTEMS AND METHODS FOR BIO-MATCHING GELS, CREAMS AND LOTIONS | 06-23-2016 |
| 20160175268 | MAGNESIUM COMPOSITIONS AND USES THEREOF FOR NEUROLOGICAL DISORDERS | 06-23-2016 |
| 20160183522 | STERILIZATION METHOD - A method of sterilizing a material, said method comprising the steps of: a) providing a sterilizing composition comprising (i) peracetic acid and (ii) a stabilizer selected from the group consisting of citric acid, isocitric acid, aconitic acid and propane-1,2,3-tricarboxylic acid; b) introducing such sterilizing composition into a hot gaseous stream to produce a peracetic acid vapor; and c) contacting such peracetic acid vapor with the material to be sterilized. The use of such an organic acid stabilizer results in an unexpected reduction in the amount of residue deposited on the heating surface employed to vaporize the sterilizing composition. | 06-30-2016 |
| 20160183523 | Methods and Compositions for the Generation of Peracetic Acid On Site at the Point-of-Use - Methods for the generation of non-equilibrium solutions of peroxyacetic acid are disclosed. These methods comprise introducing triacetin and aqueous hydrogen peroxide to water, mixing, and then adding an aqueous source of an alkali metal or earth alkali metal hydroxide. Triacetin is converted rapidly and with a high conversion rate into peracetic acid. These methods produce solutions with a high level of peracetic acid. | 06-30-2016 |
| 20160184248 | COMPOSITIONS AND METHODS OF USE OF -HYDROXY-METHYLBUTYRATE (HMB) RESULTING IN AN ACUTE ENDOCRINE RESPONSE - The present invention provides a composition comprising HMB. Methods of administering HMB to an animal are also described. HMB is administered to induce an acute endocrine response. HMB is administered to increase circulating concentrations of growth hormone (GH) and insulin-like growth factor (IGF-1). | 06-30-2016 |
| 20170231222 | COATED AGROCHEMICAL GRANULE | 08-17-2017 |
| 20170231930 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINAL DEGENERATION | 08-17-2017 |
| 20180021274 | COMPOSITIONS COMPRISING BETA-HYDROXYBUTYRIC ACID AND SALT, AND METHODS OF USING THE SAME | 01-25-2018 |
| 20190142749 | Sanguisorbigenin Polymer Micelle and Preparative Methods Thereof | 05-16-2019 |
| 20190142775 | TREATING ACTIVATED DERMAL CONDITIONS WITH AGENTS THAT TARGET ENERGY METABOLISM | 05-16-2019 |
| 20220133673 | KETONE BODY ESTERS OF S-BETA-HYDROXYBUTYRATE AND/OR S-1,3-BUTANEDIOL FOR MODIFYING METABOLIC FUNCTION - Compositions and methods for producing elevated blood levels of ketone bodies and modifying metabolic function in a mammal. Compositions include at least one ester of S-beta-hydroxybutyrate and/or a mono- or di-ester of S-1,3-butanediol and at least one ketone body component. The ketone body component includes beta-hydroxybutyrate, acetoacetate, or both. The beta-hydroxybutyrate is R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, or both. When the ketone body component is S-beta-hydroxybutyrate, the 1,3-butanediol is R-1,3-butanediol, S-1,3-butanediol, or both. Compositions may comprise a keto stack of multiple forms of ketone bodies. | 05-05-2022 |
